

Horizontal gene transfer shapes pathogenic bacteria in multiple sclerosis

Takashi Yamamura (✉ yamamura@ncnp.go.jp)

National Center of Neurology and Psychiatry

Daiki Takewaki

National Center of Neurology and Psychiatry

Yuya Kiguchi

RIKEN Center for Integrative Medical Sciences

Hiroaki Masuoka

RIKEN Center for Integrative Medical Sciences

Mallahalli Manu

National Center of Neurology and Psychiatry

Ben Raveney

National Center of Neurology and Psychiatry <https://orcid.org/0000-0003-2641-5733>

Seiko Narushima

RIKEN Center for Integrative Medical Sciences

Rina Kurokawa

RIKEN Center for Integrative Medical Sciences

Yusuke Ogata

Laboratory for Microbiome Sciences, RIKEN Center for Integrative Medical Sciences

<https://orcid.org/0000-0002-5993-4356>

Yukio Kimura

National Center of Neurology and Psychiatry

Noriko Sato

National Center of Neurology and Psychiatry

Yusuke Ozawa

National Center of Neurology and Psychiatry

Sosuke Yagishita

National Center of Neurology and Psychiatry

Toshiyuki Araki

National Center of Neurology and Psychiatry <https://orcid.org/0000-0003-3625-2042>

Sachiko Miyake

Juntendo University School of Medicine

Wakiro Sato

National Institute of Neuroscience, National Center of Neurology and Psychiatry

Wataru Suda

RIKEN Center for Integrative Medical Sciences

Biological Sciences - Article

Keywords:

Posted Date: December 8th, 2023

DOI: <https://doi.org/10.21203/rs.3.rs-3716024/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: **Yes** there is potential Competing Interest. D.Takewaki received support for research from Yakult Bio-Science Foundation. W. Sato received support for clinical trials from Chugai Pharmaceutical Co., Ltd. and Biogen Japan Ltd. T. Yamamura served on the scientific advisory board of Biogen Japan Ltd. and received support for research and clinical trials from Sanofi K.K., Chugai Pharmaceutical Co., Ltd., UCB Japan Co., Ltd., Biogen Japan Ltd., Chiome Bioscience Inc., Novartis Pharma K.K., and Mebix, Inc.

1 Horizontal gene transfer shapes pathogenic bacteria in multiple sclerosis

2

3 Authors & Affiliations

4 Daiki Takewaki^{1,2,3,9}, Yuya Kiguchi^{3,4,9}, Hiroaki Masuoka³, Mallahalli Manu^{1,2}, Ben J E Raveney^{1,2},
5 Seiko Narushima⁵, Rina Kurokawa³, Yusuke Ogata³, Yukio Kimura^{2,6}, Noriko Sato^{2,6}, Yusuke
6 Ozawa⁷, Sosuke Yagishita⁷, Toshiyuki Araki⁷, Sachiko Miyake⁸, Wakiro Sato^{1,2}, Wataru Suda^{3,10*},
7 Takashi Yamamura^{1,2,10*}

8

- 9 1. Department of Immunology, National Institute of Neuroscience, National Center of Neurology
10 and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan
- 11 2. Multiple Sclerosis Center, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi,
12 Kodaira, Tokyo 187-8502, Japan
- 13 3. Laboratory for Symbiotic Microbiome Sciences, RIKEN Center for Integrative Medical
14 Sciences, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
- 15 4. Department of Computational Biology and Medical Sciences, Graduate School of Frontier
16 Sciences, The University of Tokyo, Chiba 277-8568, Japan
- 17 5. Laboratory for Mucosal Immunity, RIKEN Center for Integrative Medical Sciences, 1-7-22
18 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan
- 19 6. Department of Radiology, National Center of Neurology and Psychiatry Hospital, 4-1-1 Ogawa-
20 Higashi, Kodaira, Tokyo 187-8502, Japan
- 21 7. Department of Peripheral Nervous System Research, National Institute of Neuroscience, National
22 Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8502, Japan
- 23 8. Department of Immunology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku,
24 Tokyo 113-8421, Japan
- 25 9. These authors contributed equally: Daiki Takewaki and Yuya Kiguchi.
- 26 10. These authors jointly supervised this work: Wataru Suda and Takashi Yamamura.

27 * **Email:** yamamura@ncnp.go.jp; wataru.suda@riken.jp

28

29 **SUMMARY**

30 Multiple sclerosis (MS) is an autoimmune demyelinating disease influenced by environmental
31 factors. Except during relapses, baseline neurological status is generally stable in the early stage,
32 whereas progressive deterioration may occur silently. The progressive disease form (secondary
33 progressive MS; SPMS) characterised by both neuroinflammation and neurodegeneration differs
34 significantly from the non-progressive form in microbiome profiles^{1 2 3}. After confirming an
35 increased abundance of gut bacterium “*Tyzzarella nexilis*” in SPMS, the role of *T.nexilis* in
36 progressive MS was studied. The strain-level analysis based on long-read metagenomics identified a
37 distinct cluster of *T.nexilis* highly enriched in SPMS. *T.nexilis* strains in this novel cluster were
38 characterised by an incredible number of mobile genetic elements (MGEs) and the absence of
39 defence systems against MGEs. Mono-colonisation with this MGEs-enriched *T.nexilis* strain made
40 germ-free mice more susceptible to induction of experimental autoimmune encephalomyelitis. The
41 pathogenicity of this strain was mediated by TLR5 stimulation by flagella encoded on MGEs.
42 Moreover, this *T.nexilis* strain was thought to have potentials of causing neurodegeneration, because
43 of its ability to produce reduced sulphur compounds encoded on MGEs. Such a horizontal gene
44 transfer, causing functional diversity beyond existing bacterial taxonomy, may have causal
45 implications in chronic disorders influenced by gut microbiome.

46

47 MAIN TEXT

48 Most patients with multiple sclerosis (MS) initially experience intermittent acute inflammation that
49 causes relapses (relapsing-remitting MS; RRMS), while some patients with RRMS shift to secondary
50 progressive MS (SPMS). SPMS is generally defined by the presence of progression independent of
51 relapse activity attributable to cytotoxic T lymphocytes^{4,5}, activated glial cells⁶, and enhanced
52 oxidative stress⁷ leading to chronic neuroinflammation and neurodegeneration.

53 Comprehensive microbial analysis has revealed dysbiosis of the gut microbiome in RRMS as
54 reported in various countries^{1 2 3 8 9 10 11}. Meanwhile, studies in the rodent model, experimental
55 autoimmune encephalomyelitis (EAE), showed that commensal microbiome affected various
56 immune cell populations including T and B lymphocytes and microglial cells, thereby regulating the
57 central nervous system (CNS) autoimmune disorder^{12 13 14 15 16}. Recent reports demonstrated that gut
58 microbiome profiles significantly differ between RRMS and SPMS^{1 2 3}. However, its biological
59 meaning remains unclear. The purpose of this research is to reveal the characteristics of causative
60 bacteria underlying MS progression and clarify the mechanism of exacerbating neuronal
61 inflammation and degeneration.

62

63 Identification of gut bacteria associated with MS progression

64 First, we investigated the composition of gut microbiomes of MS using original short-read
65 metagenomic data, followed by marker gene-based operational taxonomic unit (mOTU) analysis
66 (**Extended data Table 1**). To identify specific bacteria characteristic of SPMS, we employed
67 MaAsLin2¹⁷. In the exploratory comparison between RRMS and SPMS, 38 mOTUs were
68 significantly increased or decreased in SPMS. Among them, *Tyzzarella nexilis* (id03689) belonging
69 to Firmicutes was the most enriched species in SPMS based on the coefficient value of MaAsLin2
70 (**Fig.1a and Extended data Table 2**). In the comparison between patients with SPMS and healthy
71 control (HC) participants, 40 mOTUs were highly enriched or depleted in SPMS ($|\text{coefficient}| > 1$ and
72 $p < 0.05$ shown in **Fig.1b**). Among them, *Tyzzarella nexilis* (id03689) was the most enriched species
73 in SPMS (**Fig.1b and Extended data Fig.1a**). Next, to explore if enrichment of *T.nexilis* (id03689)
74 in progressive MS is present in other regions or countries, we conducted mOTU analysis using the
75 large-scale metagenomic data from the international MS microbiome study (iMSMS) consortium³.

76 To compare the microbial taxa with the same analytic procedure using mOTUs, we analysed 1,139
77 samples (435 RRMS, 133 progressive MS, and 571 HC). Comparisons of iMSMS samples between
78 progressive MS and HC revealed a significant enrichment of *T.nexilis* (id03689) in the three
79 progressive MS groups from Western countries (**Fig.1b and Extended data Fig.1b-d**). However, no
80 such differences were observed between RRMS and HC in most countries (**Extended data Fig.1f**).

81 We also conducted mOTU analysis using the public data of inflammatory bowel disease (IBD)¹⁸,
82 rheumatoid arthritis¹⁹, colorectal cancer²⁰, and Parkinson's disease²¹. These diseases did not show
83 enrichment of *T.nexilis* (id03689) (**Extended data Fig.1f**).

84 To validate the possible effects of immunotherapy, we compared the abundance of 40 mOTUs
85 between the untreated progressive MS and HC in the iMSMS data. The abundance of *T.nexilis*
86 (id03689) was significantly increased in progressive MS even after removing the treated patients
87 (**Fig.1b and Extended data Fig.1e**), excluding the effects of immunotherapy. We subsequently
88 conducted a correlation analysis between gut microbial abundance and expanded disability status
89 scale (EDSS) score, a clinical measure of neurological impairment, in both our original and iMSMS
90 cohorts. While the abundance of *T.nexilis* (id03689) significantly correlated with the EDSS score
91 (**Fig.1b**), the abundance of *T.nexilis* (id03689) tended to increase during the transition phase (EDSS
92 3 to 4.5) in both cohorts (**Fig.1c**). As transition from RRMS to SPMS generally occurs at EDSS 3 to
93 4.5, we suspected that the increase of *T.nexilis* may trigger progressive MS, while it decreases at later
94 points. In contrast, the other four mOTUs were positively correlated with EDSS score without bias
95 for the transition phase (**Extended data Fig.2**). Then we also conducted correlation analysis between
96 the abundance of 40 mOTUs and four quantitative brain magnetic resonance imaging (MRI)
97 parameters. The brain volume was significantly lower, and the lesion volume was significantly
98 higher in SPMS than in RRMS (**Extended data Fig.3a**), and the abundance of *T.nexilis* (id03689)
99 negatively correlated with the total brain volume and grey matter volume of these patients
100 (**Extended data Fig.3b**).

101 We further analysed the non-redundant metagenome-assembled genome (MAG) by using our
102 original metagenomic data. Based on the taxonomical assignment, two MAGs were annotated to
103 *T.nexilis*. We named one of them *T.nexilis*_strain A MAG and the other *T.nexilis*_strain B MAG.
104 Then we evaluated the number of mapped reads per million to the strain-specific marker genes

105 between *T.nexilis*_strain A and B MAGs (**Extended data Table 3**). Notably, strain B MAG was
106 significantly enriched in SPMS compared with HC and RRMS, whereas the abundance of strain A
107 MAG was not significantly different between the three groups (**Fig.1d**). The prevalence of strain B
108 MAG was much higher in SPMS (33%) than in HC (14%) and RRMS (13%) (**Fig.1e**).

109

110 **Discovery of *Tyzzarella nexilis* strains encoding numerous mobile genetic elements**

111 For high-resolution genomic analysis, we tried to obtain the high-quality genomes of *T.nexilis* from
112 selected five “*T.nexilis* (id03689)-high” patients. We successfully isolated two *T.nexilis* strains from
113 the faecal samples of RRMS_031 and SPMS_002. We performed long-read sequencing using
114 PacBio HiFi reads and obtained two complete genomes by *de novo* assembly. Additionally, we
115 performed long-read metagenomics for the other three samples and obtained metagenomic HiFi
116 reads with 19.3 Gb and 8.3 kb read lengths on average (**Extended data Table 1**). We conducted the
117 long-read metagenomic assembly for the samples from SPMS_015 and RRMS_004 and obtained the
118 three complete *T.nexilis* genomes (**Extended data Fig.4a**). For the sample from RRMS_041, we
119 performed a combinational analysis of a long-read metagenomic assembly, binning, and reference-
120 guided assembly because we could not construct complete genomes through the simple metagenomic
121 assembly (**Extended data Fig.4b**). All six genomes were closed circular and satisfied the
122 completeness >99% and contamination <2% (**Fig.2a**). Based on the phylogenetic tree of *T.nexilis*
123 genomes, we found two distinct clusters in *T.nexilis*. One included strain A MAG and the other
124 included strain B MAG (**Fig.2b**). Among the seven circular genomes, the type strain
125 (*T.nexilis*_DSM1787) and three genomes from patients with MS were clustered to the strain A
126 lineage (**Fig.2b**) and had >98.7% average nucleotide identity (ANI) with strain A MAG (**Fig.2a**).
127 Conversely, the other three genomes from patients with MS were clustered to the strain B lineage
128 (**Fig.2b**) and had >99.6% ANI with strain B MAG (**Fig.2a**). We named these novel genomes as A1,
129 A2, A3, B1, B2, and B3, respectively. Dot plot for genomic comparison also suggested that strain
130 B1, B2, and B3 had clearly different genomic structures from strain A1, A2, and A3 (**Extended data**
131 **Fig.5**). Further, we performed comparative genomics of *T.nexilis* strains. The genome size and
132 number of total genes were much larger in strain B1, B2, and B3. The number of virulent genes
133 assigned to the virulence factor database was also larger in strain B1, B2, and B3. Notably, the

134 number of mobile genetic elements (MGEs) that are closely associated with the bacterial horizontal
135 gene transfer, including insertion sequences (IS), prophages, and integrative and conjugative
136 elements (ICE), was much larger in strain B1, B2, and B3 (**Fig.2c**). Then, we analysed various
137 defence systems that protect bacteria from MGEs, among which CRISPR-Cas9 (CAS_Class1) works
138 against various types of MGEs²² as well as restriction modification (RM). Notably, the number of
139 defence systems was much smaller in strain B1, B2, and B3 (**Fig.2c**). Moreover, an incredibly large
140 number of MGEs found in the strain B1, B2, and B3 were outstanding among the 727 representative
141 Firmicutes genomes in the GenBank (**Fig.2d and Extended data Table 4**). The genomes of strain
142 B1, B2, and B3 have an average of nine times larger ISs, 18 times larger ICEs, and three times larger
143 prophages than the average of the Firmicutes genomes. In the process of the comparison between
144 two strain B1 genomes from short-read MAG and isolation-based complete genome, we realised that
145 a large number of MGEs were not detected in the short-read MAG (**Extended data Fig.6**), which
146 suggested the superiority of long-read metagenomics over short-read metagenomics. This is why we
147 have not used fragmented genomes for the comparison of *T.nexilis* strains.

148

149 **Functional significance of *Tyzzarella nexilis* strains**

150 Subsequently, we conducted *in vivo* bacterial transfer experiments using two isolated *T.nexilis* strains
151 belonging to distinct clusters (**Fig.3a**). Germ-free mice were administered *T.nexilis*_strain A1 or B1
152 in culture media one and two weeks before sensitisation to myelin oligodendrocyte glycoprotein
153 (MOG) peptide fragment 35-55 (MOG₃₅₋₅₅). Colonisation with these bacteria was confirmed by
154 quantitative PCR (qPCR) using universal primers for 16S rRNA genes one week after the last
155 bacterial administration (**Extended data Fig.7a**). Strain B1-colonised mice showed an increased
156 severity of EAE symptoms compared with germ-free mice, whereas colonisation with strain A1
157 showed the restricted effects (**Fig.3b**). The frequency of T helper 17 (Th17) cells among CD4⁺ T
158 cells in the small-intestinal lamina propria (SILP), large-intestinal lamina propria (LILP), and CNS
159 was much higher in strain A1 or B1 mono-colonised mice than in germ-free mice. Moreover, the
160 frequency of Th17 cells in strain B1 mono-colonised mice was significantly higher than in strain A1
161 mono-colonised mice in the LILP and CNS (**Fig.3c, d**). The frequency of regulatory T cells in the

162 SILP, LILP, and CNS was not significantly different between strain A1 and B1 mono-colonised mice
163 (**Extended data Fig.7b, c**).

164 To elucidate the mechanism with which strain B1 caused severe EAE symptoms compared to strain
165 A1, we compared the complete genomes of these two strains. We annotated open reading frames
166 (ORFs) of each genome based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database
167 and compared the differences of the number of KEGG orthologies (KOs) in each pathway. Among
168 them, we analysed the four most enriched pathways in strain B1 (**Fig. 3e**). Initially, we focused on
169 the pathways “flagellar assembly” and “bacterial chemotaxis,” both related to flagellar functions. As
170 flagellin is a selective agonist of toll-like receptor 5 (TLR5), we addressed whether each *T.nexilis*
171 strain had a differential ability to stimulate TLR5. Using TLR5-reporter cells, we confirmed that
172 strain B1, but not strain A1, stimulated TLR5, suggesting that strain B1 possesses flagella (**Fig.3f**).

173 Consistently, a flagella-like structure in strain B1 was confirmed using scanning electron microscopic
174 (SEM) images (**Fig.3g**). Then, we co-cultured specific pathogen-free mice-derived CD11c^{high}
175 CD11b^{high} intestinal lamina propria dendritic cells (LPDCs) (a TLR5-expressing LPDC population)²³
176 with each *T. nexilis* strain in the presence or absence of a TLR5 antagonist. Co-culture of the LPDCs
177 with strain B1 promoted the secretion of IL-6 in the supernatant compared to that with strain A1.

178 However, the supplementation with a TLR5 antagonist almost completely suppressed the secretion
179 of IL-6 from the LPDCs. These findings suggested that *T.nexilis*_strain B1 can stimulate TLR5
180 expressed by intestinal LPDCs and subsequently induce the secretion of IL-6 (**Fig.3h**). Next, we

181 focused on another flagellar function, which is promoting adherence to intestinal epithelial cells
182 (ECs)²⁴. To verify the bacterial adherence on the intestinal ECs, we prepared strain A1 or B1 mono-
183 colonised mice. After cleaning up the intestinal contents, we observed the surface of the colon.

184 Although no bacteria were detected on the colonic ECs of strain A1 mono-colonised mice despite
185 sufficient colonisation (**Extended data Fig.7a**), many bacteria were found to be adherent to the ECs
186 of the proximal colon in strain B1 mono-colonised mice (**Fig.3i**). Then, we examined the effects of
187 strain B1 adhesion on colonic EC gene expression profiles using RNA-sequencing. Gene ontology
188 (GO) analysis revealed that various biological process terms possibly related to immune activation
189 and defence response against invasive bacteria such as immune system process (GO: 0002376),
190 immune response (GO: 0006955), and defence response (GO: 0006952) were highly enriched in the

191 colonic ECs of strain B1 mono-colonised mice compared with those of strain A1 mono-colonised
192 mice (**Extended data Fig.7d**). In consistence with this result, the expression of α -defensin genes was
193 upregulated in the strain B1 mono-colonised mice (**Extended data Fig.7e**). Among various
194 upregulated genes, we particularly focused on the serum amyloid A (SAA) genes because prior
195 studies showed that SAA1 secreted from the intestinal ECs upon bacterial adherence promotes Th17
196 cell differentiation^{13 25}. By conducting RNA-sequencing and qPCR analyses, we observed a
197 significant increase in *SAA1* expression in the colonic ECs of strain B1 mono-colonised mice (**Fig.3j**
198 **and Extended data Fig.7f**). To verify the biological significance of the enrichment of IL-6 and
199 SAA1 in the local environment, we conducted an *in vitro* assay for the activation of naive CD4⁺ T
200 cells. We observed that a combination of IL-6 and SAA1 robustly promoted the secretion of IL-17
201 and GM-CSF from the activated T cells compared with IL-6 and TGF- β (the combination for non-
202 pathogenic Th17 cell differentiation) under T cell stimulations of different strength via anti-
203 CD3/CD28 antibodies (**Fig.3k, l**). In a previous paper, the combination of IL-6 and SAA1 was
204 reported to promote a higher expression of genes related to pathogenic Th17 cells, including *Tbx21*,
205 *Gzmb*, and *IL-23R* in activated T cells, as compared with the combination of IL-6 and TGF- β and
206 subsequently exacerbated CNS autoimmunity²⁶. Collectively, we postulate that the strain B1-flagella
207 probably accelerate neuronal inflammation via the combination of TLR5 stimulation and promotion
208 of adherence to colonic ECs. Then, we evaluated the abundance of strain B1-flagellar genes among
209 HC, RRMS, and SPMS. We focused on *fliC* genes because *fliC* encodes a filament of flagella that
210 contains the epitope of the TLR5 ligand. The number of mapped reads per million to *fliC* genes of
211 strain B1 was significantly increased in SPMS, suggesting that the strain B1-flagella are enriched in
212 SPMS (**Fig.3m**). The pathway “cationic antimicrobial peptide (CAMP) resistance” was also enriched
213 in strain B1. In this pathway, 4 KOs included in strain B1 were mapped to the module *dltABCD*
214 operon (M00725), which is associated with increased resistance to CAMPs such as α -defensin²⁷
215 (**Extended data Fig.7g**). High expression of α -defensin genes in colonic ECs of strain B1-
216 monocolonised mice implied the CAMP resistance in strain B1 (**Extended data Fig.7e**). Finally, we
217 focused on the pathway “sulphur metabolism.” In this pathway, 4 and 1 KOs included in strain B1
218 (not in strain A1) were mapped to the module assimilatory sulphate reduction (M00176) and
219 dissimilatory sulphate reduction (M00596), respectively (**Fig.3n**). To confirm the effects of strain B1

220 on sulphur metabolism in the gut, we analysed the concentration of 30 sulphur metabolites in the
221 faeces of germ-free and strain A1 or B1 mono-colonised mice. The ratio of glutathione (reductive
222 form) to glutathione disulphide (oxidative form), a quantitative indicator of redox states²⁸, was
223 significantly higher in strain B1 than in strain A1 (**Fig. 3o**). We also measured the production of
224 hydrogen sulphide (H₂S) in the gas phase of sealed liquid culture media of strain A1 and B1 because
225 H₂S is a terminal product of sulphate reduction. The production of H₂S was higher in strain B1 than
226 in strain A1 (**Fig.3p**).

227 228 **Mechanisms for the acquisition of the potentially pathogenic genes**

229 The prominent accumulation of MGEs in *T.nexilis*_strain B1 urged us to explore the origin of these
230 potentially pathogenic genes. The comparison of seven *T.nexilis* genomes revealed that 11 KOs in
231 “flagella assembly” and 10 KOs in “sulphur metabolism” were present in the genomes of cluster B
232 but absent in those of cluster A, although the average similarity of 16S rRNA genes between cluster
233 A and B was more than 99.2% (**Extended data Fig.8 and Extended data Table 5**). Initially, we
234 focused on several genes related to sulphur metabolism. In the specific region of the strain B1
235 genome, four sulphur metabolic genes were aligned to phage proteins with >75% amino acid identity
236 on average (**Fig.4a**), and a 25kb region that included sulphur metabolic genes was aligned to an
237 isolated *Ruminococcus gnavus* strain (strain AF33-12²⁹) with >99% nucleotide similarity (**Fig.4a**).
238 Although we could not find obvious characteristics of known MGEs in this genomic region encoding
239 a sulphur metabolic gene cluster, these results suggest that horizontal transmission had occurred
240 between *T. nexilis* and *R.gnavus*, a prevalent gut species with pathogenic potentials whose
241 enrichment was reported in various diseases³⁰.

242 Then, we explored flagellar genes highly similar to those of strain B1 in public bacterial genomes
243 obtained from a variety of environments^{31 32 33}. However, we could not find any relevant results,
244 which prompted us to devise a different strategy. We attempted to recapitulate the evolutionary
245 history of a *fliC* gene based on the genomes of various bacterial species with flagellar genes.
246 Specifically, we collected human gut bacterial genomes encoding *fliC* from the HumGut database
247 and constructed the phylogenetic tree of *fliC* including the four genes of *T.nexilis*_strain B1. The *fliC*
248 genes of strain B1 were clustered within the Firmicutes (**Extended data Fig.9**). The phylogenetic

249 tree of Firmicutes genomes based on the taxonomic marker genes consisted of five clusters at an
250 order level and had *T.nexilis*_strain B1 in a cluster of the Lachnospirales (**Fig.4b**). The phylogenetic
251 tree of *fliC* genes also consisted of several clusters generally consistent with classification at the
252 order-level; however, the *fliC* genes of *T.nexilis*_strain B1 were located within a cluster of the
253 Oscillospirales (**Fig.4c**). These conflicts between bacterial taxonomy and phylogeny of *fliC*
254 suggested that the strain B1-*fliC* genes were acquired by horizontal gene transfer. Moreover, the
255 phylogenetic tree of *fliC* indicates that the strain B1-*fliC* was initially derived from Oscillospirales.
256 Finally, to clarify the genomic structure of this flagella-horizontal gene transfer region in the
257 *T.nexilis*_strain B1, we compared the two bacterial genomes of strain B1 and B2 because the genome
258 of strain B2 does not include any flagellar genes (**Extended data Fig.8**) although strain B1 and B2
259 are phylogenetically close with >99.6% 16S rRNA gene similarity. In the comparison of these two
260 genomes, we could determine the edge of the flagella-horizontal gene transfer region which does not
261 exist in the strain B2 genome and is flanked by two direct terminal repeats and the IS family 91
262 (IS91) (**Fig.4d**). These results suggest that this flagella-horizontal gene transfer region spanning one
263 IS91 to the other IS91 was transferred as a single unit called as composite transposon³⁴. Interestingly,
264 typical ICE signatures such as the presence of ICE marker genes, alteration of the GC content and
265 skew, and the direct terminal repeat at the candidate boundaries of the ICE were found inside the
266 structure of the composite transposon (**Fig.4d**). Moreover, 18 out of 22 ICE-related genes were
267 aligned to ICE-derived genes from *Clostridioides difficile* with 90% amino acid identity on average
268 (**Extended data Table 6**). As physical contact between bacteria is necessary for ICE acquisition,
269 these results imply the past event of conjugative interaction between *T.nexilis*_strain B1 and
270 *Clostridioides difficile*.

271

272 **Discussion**

273 The gut microbiome altered in progressive MS appears to influence the neuronal inflammation and
274 degeneration^{1 2 3}. To understand the correlation of altered microbiome components to the brain
275 disorder, we sought a pathogenic bacterium triggering or boosting MS progression. Comprehensive
276 metagenomic analysis revealed that “*Tyzzarella nexilis*” was the most significantly enriched species
277 in SPMS compared to RRMS and HC. Notably, it was an exceptional bacterium whose abundance
278 was significantly correlated with neurological disability and showed an inverse correlation with the
279 brain volume of the patients. Its enrichment in patients with progressive MS was also confirmed in
280 Western cohorts during the critical phase of EDSS 3 to 4.5, corresponding to the border between
281 RRMS and SPMS³. The specific increase of *T.nexilis* prior to the definitive development of SPMS
282 might indicate a causative role in MS progression. Recently, the immunogenicity of this species has
283 gained much attention because *T.nexilis* stimulated a wide variety of T cell receptor repertoire
284 against various bacterial antigens in contrast to other commensal species³⁵.

285 While analysing various *T.nexilis* strains, we identified a novel cluster of *T.nexilis* strains that was
286 specifically enriched in SPMS. Mono-colonisation with *T.nexilis*_strain B1 from this cluster
287 rendered germ-free mice more susceptible to EAE induction. Genome comparison between strain A1
288 and B1, belonging to distinct clusters, revealed numerous differences. In particular, specific genes
289 associated with sulphate reduction and flagella formation were specifically associated with strain B1.
290 In the present study, sulphate reduction was accelerated in the gut of strain B1 mono-colonised mice,
291 and the liquid culture of strain B1 produced abundant H₂S, a terminal product of sulphate reduction.
292 Although the pathological role of H₂S in neurodegenerative disorders remains controversial³⁶,
293 excessive H₂S is linked to neurodegenerative diseases, including amyotrophic lateral sclerosis
294 (ALS)^{36 37 38}. The concentration of H₂S in the cerebrospinal fluid was maintained at a high level in
295 patients with sporadic ALS³⁷, and the disease-enhancing effect of H₂S as a glial-released
296 inflammatory factor was confirmed in several studies using an animal model of ALS^{37 38}. Moreover,
297 the enrichment of sulphate-reducing bacteria in the gut of patients with Parkinson’s disease and the
298 active involvement of gut-derived H₂S in the pathogenesis of this disease were reported³⁹.

299 Considering various similarities between these neurodegenerative disorders and progressive MS, the

300 promotion of sulphate reduction accompanied by H₂S production in the gut might exacerbate
301 neurodegeneration.

302 On the other hand, the strain B1-derived flagella would provoke over-production of IL-6 by
303 CD11c^{high}CD11b^{high} LPDCs via TLR5 stimulation. We also obtained morphological evidence that
304 strain B1 adheres to the gut epithelium across the mucus barrier. This is probably due to the presence
305 of the flagella, as flagellated motile bacteria can swim into an inner mucus layer where most of the
306 other commensal bacteria cannot exist²⁴. The close attachment of strain B1 to the gut epithelium
307 provokes the secretion of SAA1. Combined effects of TLR5 signals and SAA1 were thought to
308 induce pathogenic Th17 cells and exacerbate neuroinflammation²⁶. In the present study, we analysed
309 the specific mechanism for bystander activation of pathogenic T cells rather than that for antigen-
310 specific T cell responses because of the following limitations: true CNS autoantigens have not been
311 fully elucidated in patients with MS and major histocompatibility complex diversity causes
312 inconsistent antigen-specific T cell reactivities between individuals (in contrast to EAE). However,
313 considering the previous findings indicating a cross-reaction of T cells between MOG peptides and
314 commensal bacteria-derived proteins in an EAE model¹³, a similar mechanism may exist in patients
315 with MS, which warrants further investigation.

316 Remarkably, the genes related to the flagella in strain B1 were thought to be horizontally-transferred,
317 based on the detailed genome analysis between strain B1 and B2, where each strain underwent its
318 own evolution under the common characteristics of vulnerability to MGEs, resulting in genomic
319 diversities including with or without flagellar genes. On the other hand, these strains are enriched in
320 various virulent genes as a common feature of strains included in this novel cluster of *T.nexilis*.

321 Initially, we focused on strain B1-flagellar genes because we confirmed its pathogenicity and
322 enrichment in SPMS (**Fig.3**). However, this was only an example and we soon noticed that the
323 genomes of strain B1, B2, and B3 contained exceptionally high numbers of horizontally-transferred
324 genes, having pathogenic implications. As known, frequent exchanges of MGEs between bacteria
325 promote the spread of functional traits such as antibiotic resistance and exotoxins^{40 41}. However,
326 bacterial horizontal gene transfer in chronic human diseases has rarely been investigated in the
327 context of pathogenic implications. Notably, anti-MGEs defence systems in strain B1, B2, and B3
328 were greatly reduced, indicating their relationships with horizontal gene transfer. We speculated that

329 the MGEs-enriched strains were selected in the potentially harsh environment by reducing their anti-
330 MGEs defence systems to acquire advantageous auxiliary genes via horizontal gene transfer.

331 In the present study, we observed an enrichment of several genes related to sulphate reduction in
332 strain B1, B2, and B3 with the deviation of faecal sulphur metabolites towards potentially reductive
333 states. Similarities of these genes between *T.nexilis*_strain B1 and *R.gnavus*_strain AF33-12
334 suggested that these genes are encoded on MGEs. Moreover, four sulphur related genes included in
335 strain B1, B2, and B3 (but not in strain A1, A2, and A3) were similar to those of phage genomes,
336 which is consistent with the previous finding showing that many microbial genes related to sulphur
337 metabolism are encoded on prophages⁴². Considering that several sulphate-reducing bacteria have
338 resistance to oxidative stress⁴³, this feature may affect the survival of strain B in an oxidative
339 environment. Further, strain B1, B2, and B3, but not strain A1, A2, and A3, had several resistant
340 genes for CAMP (*dltABCD* operon). CAMP is a critical contributor to host defence against invasive
341 bacteria. This property might indicate that these bacteria could survive in an environment where the
342 activation of innate immunity occurs, and other susceptible bacteria cannot survive. During the
343 process of acquiring MGEs, the bacteria obtain genes for them to adapt to the environment; however,
344 the acquired genes may potentially promote chronic disorders such as MS. The elucidation of the
345 evolutionary history and ecological niche of *T.nexilis* will help us to understand the precise
346 mechanism of how pathogenic bacteria are shaped in the process of evolution.

347 Although our patient cohort was relatively small, the significant increase of *T.nexilis* (id03689) in
348 untreated progressive MS, which may include both SPMS and primary progressive MS (PPMS), was
349 confirmed by the metagenomic analysis using the large-scale validation cohort in Western countries³.

350 As we could not recruit a sufficient number of patients with PPMS due to a low prevalence of the
351 patients in Japan⁴⁴, it remains to be seen if PPMS is also characterised by increased numbers of
352 *T.nexilis*. As *T.nexilis*_strain B is a novel cluster that we had never isolated, we encountered many
353 difficulties in adding a genetic modification to strain B1, such as targeting flagellar genes. However,
354 sequential results based on the comparison of several strains belonging to the same species suggested
355 the significant role of strain B1-flagella in the context of chronic neuroinflammation.

356 In summary, we demonstrated that horizontal transfer of functional genes may determine the
357 pathogenicity of gut bacteria underlying chronic disorders such as MS (**Extended data Fig.10**).

358 The lack of defence systems and enrichment of MGEs in disease-associated bacteria might be a
359 promising therapeutic target in various diseases influenced by the gut microbiome.

360

361 **FIGURE LEGENDS**

362 **Fig.1. Identification of gut bacteria associated with MS progression**

363 (a) The coefficient value based on MaAsLin2 and $-\log_{10} p$ -value obtained from the comparison
364 between the 62 patients with RRMS and 15 patients with SPMS are shown in the volcano plot. (b)
365 Global microbiome alterations in progressive MS compared with HC. SPMS-enriched or depleted (p
366 < 0.05 and $|\text{coefficient}| > 1$) mOTUs are shown in the left column. The differences of these SPMS-
367 enriched or depleted mOTUs in the comparison between the progressive MS and HC groups in each
368 country using the validation cohort of international MS microbiome study (iMSMS) are shown. A
369 coefficient value based on MaAsLin2 in the comparison between the disease and healthy groups is
370 depicted from the lowest (blue) to the highest (red) according to the scale shown on the right. The
371 coefficient values based on MaAsLin2 in the correlation between the relative abundance of each
372 mOTU and an expanded disability scale (EDSS) score in the original and iMSMS cohorts are
373 depicted from the lowest (purple) to the highest (orange) according to the scale shown on the right.
374 (c) The relative abundance of *Tyzzarella nexilis* (id03689) at each EDSS score separately in the
375 original ($n = 77$) and iMSMS ($n = 568$) cohorts of patients with MS. The non-linear regression
376 curves for the average of the relative abundance in each EDSS group are shown in red. (d-e) Number
377 of mapped reads per million (RPM) to the 11 strain-specific marker genes between *T.nexilis*_strain A
378 and B MAGs (d) and their prevalence (e) among the 29 HCs, 62 patients with RRMS, and 15
379 patients with SPMS. Data are presented as the mean \pm S.D. ns $p > 0.05$, * $p < 0.05$; MaAsLin2.

380

381 **Fig.2. Genome comparison among various *Tyzzarella nexilis* strains**

382 (a) Schematic representation of the strategy for construction of complete *T.nexilis* genomes. Five
383 faecal samples derived from patients with RRMS and SPMS were selected as sources of *T.nexilis*
384 strains. Closed circular genomes were obtained from two isolated strains (*T.nexilis*_strain A1 and
385 B1) and from four non-isolated strains (*T.nexilis*_strain A2, A3, B2, and B3). The structure of the six
386 closed circular *T.nexilis* genomes is shown. The average nucleotide identity (ANI) between
387 *T.nexilis*_strain A MAG (or strain B MAG) and the obtained *T.nexilis* genomes is shown. (b)
388 Phylogenetic tree of the short-read MAGs, seven closed circular genomes, and publicly available 12
389 genomes of *T.nexilis* based on 120 bacterial marker genes. (c) Comparisons of the various genomic

390 characteristics among various *T.nexilis* genomes [number of total genes, number of virulent genes in
391 VFDB, number of insertion sequence (IS)/ prophage/ integrative and conjugative elements (ICE),
392 and number of defence system]. The presence or absence of anti-MGE defence systems including
393 Abortive infection (Abi), CRISPR-Cas9, DISARM, Gao, Hachiman, Restriction modification (RM),
394 and Wadjet is also shown. The z-score based on the number of genes is depicted from the lowest
395 (blue) to the highest (red) according to the scale shown on the right. (d) Comparisons of the number
396 of mobile genetic elements among the 727 representative Firmicutes genomes in the GenBank and
397 seven *T.nexilis* strains.

398

399 **Fig.3. Functional characteristics of *Tyzzarella nexilis* strains**

400 (a) Schematic of the experimental flow. (b) EAE score of germ-free (GF) mice inoculated with
401 *T.nexilis*_strain A1 or B1. Combined results of two independent experiments are shown (GF, n=13;
402 strain A1 and B1, n=11). (c) Representative FACS plots (gated on CD3⁺CD4⁺CD8⁻). (d) Frequency
403 of Th17 cells in the small intestine (n=5 mice), large intestine (n=5 mice), and central nervous
404 system (GF, n=13; strain A1 and B1, n=11). (e) Differences of gene contents between strain A1 and
405 B1 based on KEGG pathways. (f) Co-culture of heat-inactivated strains with TLR5 reporter HEK
406 cells. (g) SEM images of cultured strains. A flagella-like structure is indicated by an arrow. (h) Co-
407 culture of heat-inactivated strains with CD11c^{high}CD11b^{high} intestinal dendritic cells. (i) SEM images
408 on the surface of the colon in the mono-colonised mice. (j) Gene expression of *SAA1* on the colonic
409 epithelial cells was assessed by qPCR. (k, l) The assay for Th17 cell differentiation. The
410 concentrations of IL-17 (k) and GM-CSF (l) were assessed by ELISA. (m) Number of mapped reads
411 per million (RPM) to *fliC* genes of *T.nexilis*_strain B1 among the 29 HCs, 62 RRMS, and 15 SPMS
412 patients. (n) The presence or absence of KEGG orthologies (KOs) included in strain B1 but not in
413 strain A1 in each module within sulphur metabolism (map00920). (o) The ratio of glutathione to
414 glutathione disulphide in the faeces of GF and strain A1 or B1 mono-colonised mice (n=3 mice). (p)
415 The production of hydrogen sulphide (H₂S) in YCFA liquid culture media was assessed by lead
416 acetate paper. Data are presented as the mean ± S.D. ns $p > 0.05$, * $p < 0.05$, ** $p < 0.01$, *** $p <$
417 0.001 , **** $p < 0.0001$; Kruskal-Wallis test with Dunn's multiple comparisons test (b, m), two-sided
418 unpaired t-test (d, k, l), one-way ANOVA with Tukey's multiple comparisons test (f, h, j, o).

419 **Fig.4. Acquisition mechanism of potentially pathogenic genes**

420 (a) Genomic comparison between *Tyzzarella nexilis*_strain B1 and *Ruminococcus gnavus*_strain
421 AF33-12. The ORF annotations of sulphur metabolic genes and phage-aligned sulphur metabolic
422 genes are shown coloured in red and blue, respectively. Grey connections indicate conserved regions
423 between two genomes. (b) Phylogenetic tree of the Firmicutes genomes encoding *fliC* genes from the
424 *T.nexilis*_strain B1 and HumGut based on 120 bacterial marker genes. Each colour shows the order
425 of each genome. (c) Phylogenetic tree of the *fliC* genes from *T.nexilis*_strain B1 and HumGut
426 database in five orders in Firmicutes. Each branch colour shows the order of the genomes encoding
427 *fliC* genes. (d) Genomic comparison between *T.nexilis*_strain B1 (with flagellar genes) and B2
428 (without flagellar genes). The ORF annotations of flagellar genes, ICE-related genes, and ICE
429 signature genes are shown coloured in red, blue, and brown, respectively. Insertion sequence (IS)
430 regions are shown as blue boxes. The name of each IS indicates a family of IS and IS new means a
431 novel family of IS. Grey connections indicate conserved regions between two genomes. The direct
432 terminal repeat sequences and the coordinate at the edge of ICE and composite transposon including
433 flagellar genes are shown with dashed lines of blue and black, respectively.

434

435 **MAIN REFERENCES**

- 436 1 Takewaki, D. *et al.* Alterations of the gut ecological and functional microenvironment in
437 different stages of multiple sclerosis. *Proc Natl Acad Sci U S A* **117**, 22402–22412,
438 doi:10.1073/pnas.2011703117 (2020).
- 439 2 Cox, L. M. *et al.* Gut Microbiome in Progressive Multiple Sclerosis. *Ann Neurol*,
440 doi:10.1002/ana.26084 (2021).
- 441 3 Gut microbiome of multiple sclerosis patients and paired household healthy controls
442 reveal associations with disease risk and course. *Cell* **185**, 3467–3486. e3416,
443 doi:10.1016/j.cell.2022.08.021 (2022).
- 444 4 Raveney, B. J. *et al.* Eomesodermin-expressing T-helper cells are essential for chronic
445 neuroinflammation. *Nat Commun* **6**, 8437, doi:10.1038/ncomms9437 (2015).
- 446 5 Raveney, B. J. E. *et al.* Involvement of cytotoxic Eomes-expressing CD4₍₊₎ T cells in
447 secondary progressive multiple sclerosis. *Proc Natl Acad Sci U S A* **118**,
448 doi:10.1073/pnas.2021818118 (2021).
- 449 6 Absinta, M. *et al.* A lymphocyte–microglia–astrocyte axis in chronic active multiple
450 sclerosis. *Nature* **597**, 709–714, doi:10.1038/s41586-021-03892-7 (2021).
- 451 7 Lassmann, H., van Horssen, J. & Mahad, D. Progressive multiple sclerosis: pathology and
452 pathogenesis. *Nature reviews. Neurology* **8**, 647–656, doi:10.1038/nrneurol.2012.168
453 (2012).
- 454 8 Miyake, S. *et al.* Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with
455 a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. *PLoS One* **10**,
456 e0137429, doi:10.1371/journal.pone.0137429 (2015).
- 457 9 Jangi, S. *et al.* Alterations of the human gut microbiome in multiple sclerosis. *Nat*
458 *Commun* **7**, 12015, doi:10.1038/ncomms12015 (2016).
- 459 10 Berer, K. *et al.* Gut microbiota from multiple sclerosis patients enables spontaneous
460 autoimmune encephalomyelitis in mice. *Proc Natl Acad Sci U S A* **114**, 10719–10724,
461 doi:10.1073/pnas.1711233114 (2017).

- 462 11 Cekanaviciute, E. *et al.* Gut bacteria from multiple sclerosis patients modulate human T
463 cells and exacerbate symptoms in mouse models. *Proc Natl Acad Sci U S A* **114**, 10713–
464 10718, doi:10.1073/pnas.1711235114 (2017).
- 465 12 Yokote, H. *et al.* NKT cell-dependent amelioration of a mouse model of multiple
466 sclerosis by altering gut flora. *Am J Pathol* **173**, 1714–1723,
467 doi:10.2353/ajpath.2008.080622 (2008).
- 468 13 Miyauchi, E. *et al.* Gut microorganisms act together to exacerbate inflammation in spinal
469 cords. *Nature* **585**, 102–106, doi:10.1038/s41586-020-2634-9 (2020).
- 470 14 Kadowaki, A. *et al.* Gut environment-induced intraepithelial autoreactive CD4₍₊₎ T cells
471 suppress central nervous system autoimmunity via LAG-3. *Nat Commun* **7**, 11639,
472 doi:10.1038/ncomms11639 (2016).
- 473 15 Rojas, O. L. *et al.* Recirculating Intestinal IgA-Producing Cells Regulate
474 Neuroinflammation via IL-10. *Cell* **176**, 610–624. e618,
475 doi:10.1016/j.cell.2018.11.035 (2019).
- 476 16 Hosang, L. *et al.* The lung microbiome regulates brain autoimmunity. *Nature* **603**, 138–
477 144, doi:10.1038/s41586-022-04427-4 (2022).
- 478 17 Mallick, H. *et al.* Multivariable association discovery in population-scale meta-omics
479 studies. *PLoS Comput Biol* **17**, e1009442, doi:10.1371/journal.pcbi.1009442 (2021).
- 480 18 Lloyd-Price, J. *et al.* Multi-omics of the gut microbial ecosystem in inflammatory bowel
481 diseases. *Nature* **569**, 655–662, doi:10.1038/s41586-019-1237-9 (2019).
- 482 19 Zhang, X. *et al.* The oral and gut microbiomes are perturbed in rheumatoid arthritis and
483 partly normalized after treatment. *Nature medicine* **21**, 895–905,
484 doi:10.1038/nm.3914 (2015).
- 485 20 Thomas, A. M. *et al.* Metagenomic analysis of colorectal cancer datasets identifies cross-
486 cohort microbial diagnostic signatures and a link with choline degradation. *Nature*
487 *medicine* **25**, 667–678, doi:10.1038/s41591-019-0405-7 (2019).
- 488 21 Wallen, Z. D. *et al.* Metagenomics of Parkinsons disease implicates the gut microbiome
489 in multiple disease mechanisms. *Nat Commun* **13**, 6958, doi:10.1038/s41467-022-
490 34667-x (2022).

- 491 22 Marraffini, L. A. & Sontheimer, E. J. CRISPR interference limits horizontal gene transfer
492 in staphylococci by targeting DNA. *Science (New York, N. Y.)* **322**, 1843–1845,
493 doi:10.1126/science.1165771 (2008).
- 494 23 Uematsu, S. *et al.* Regulation of humoral and cellular gut immunity by lamina propria
495 dendritic cells expressing Toll-like receptor 5. *Nat Immunol* **9**, 769–776,
496 doi:10.1038/ni.1622 (2008).
- 497 24 Haiko, J. & Westerlund-Wikstrom, B. The role of the bacterial flagellum in adhesion and
498 virulence. *Biology (Basel)* **2**, 1242–1267, doi:10.3390/biology2041242 (2013).
- 499 25 Atarashi, K. *et al.* Th17 Cell Induction by Adhesion of Microbes to Intestinal Epithelial
500 Cells. *Cell* **163**, 367–380, doi:10.1016/j.cell.2015.08.058 (2015).
- 501 26 Lee, J. Y. *et al.* Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote
502 Inflammatory Disease. *Cell* **180**, 79–91 e16, doi:10.1016/j.cell.2019.11.026 (2020).
- 503 27 Peschel, A. *et al.* Inactivation of the *dlt* operon in *Staphylococcus aureus* confers
504 sensitivity to defensins, protegrins, and other antimicrobial peptides. *J Biol Chem* **274**,
505 8405–8410, doi:10.1074/jbc.274.13.8405 (1999).
- 506 28 Yamada, K. *et al.* Characterization of sulfur-compound metabolism underlying wax-
507 ester fermentation in *Euglena gracilis*. *Scientific reports* **9**, 853, doi:10.1038/s41598-
508 018-36600-z (2019).
- 509 29 Zou, Y. *et al.* 1,520 reference genomes from cultivated human gut bacteria enable
510 functional microbiome analyses. *Nat Biotechnol* **37**, 179–185, doi:10.1038/s41587-
511 018-0008-8 (2019).
- 512 30 Crost, E. H., Coletto, E., Bell, A. & Juge, N. *Ruminococcus gnavus*: friend or foe for human
513 health. *FEMS Microbiol Rev* **47**, doi:10.1093/femsre/fuad014 (2023).
- 514 31 OLeary, N. A. *et al.* Reference sequence (RefSeq) database at NCBI: current status,
515 taxonomic expansion, and functional annotation. *Nucleic Acids Res* **44**, D733–745,
516 doi:10.1093/nar/gkv1189 (2016).
- 517 32 Fullam, A. *et al.* proGenomes3: approaching one million accurately and consistently
518 annotated high-quality prokaryotic genomes. *Nucleic Acids Res* **51**, D760–d766,
519 doi:10.1093/nar/gkac1078 (2023).

- 520 33 Pasoli, E. *et al.* Extensive Unexplored Human Microbiome Diversity Revealed by Over
521 150,000 Genomes from Metagenomes Spanning Age, Geography, and Lifestyle. *Cell* **176**,
522 649–662. e620, doi:10.1016/j.cell.2019.01.001 (2019).
- 523 34 Ross, K. *et al.* TnCentral: a Prokaryotic Transposable Element Database and Web Portal
524 for Transposon Analysis. *mBio* **12**, e0206021, doi:10.1128/mBio.02060–21 (2021).
- 525 35 Nagashima, K. *et al.* Mapping the T cell repertoire to a complex gut bacterial community.
526 *Nature*, doi:10.1038/s41586–023–06431–8 (2023).
- 527 36 Tripathi, S. J., Chakraborty, S., Miller, E., Pieper, A. A. & Paul, B. D. Hydrogen sulfide
528 signalling in neurodegenerative diseases. *Br J Pharmacol*, doi:10.1111/bph.16170
529 (2023).
- 530 37 Davoli, A. *et al.* Evidence of hydrogen sulfide involvement in amyotrophic lateral
531 sclerosis. *Ann Neurol* **77**, 697–709, doi:10.1002/ana.24372 (2015).
- 532 38 Spalloni, A. *et al.* Impact of Pharmacological Inhibition of Hydrogen Sulphide Production
533 in the SOD1G93A–ALS Mouse Model. *Int J Mol Sci* **20**, doi:10.3390/ijms20102550
534 (2019).
- 535 39 Huynh, V. A., Takala, T. M., Murros, K. E., Diwedi, B. & Saris, P. E. J. Desulfovibrio
536 bacteria enhance alpha–synuclein aggregation in a *Caenorhabditis elegans* model of
537 Parkinsons disease. *Front Cell Infect Microbiol* **13**, 1181315,
538 doi:10.3389/fcimb.2023.1181315 (2023).
- 539 40 Moura de Sousa, J., Lourenço, M. & Gordo, I. Horizontal gene transfer among host–
540 associated microbes. *Cell Host Microbe* **31**, 513–527, doi:10.1016/j.chom.2023.03.017
541 (2023).
- 542 41 Ma, Y. *et al.* Epsilon toxin–producing *Clostridium perfringens* colonize the multiple
543 sclerosis gut microbiome overcoming CNS immune privilege. *J Clin Invest* **133**,
544 doi:10.1172/jci163239 (2023).
- 545 42 Johansen, J. *et al.* Centenarians have a diverse gut virome with the potential to modulate
546 metabolism and promote healthy lifespan. *Nature microbiology* **8**, 1064–1078,
547 doi:10.1038/s41564–023–01370–6 (2023).

- 548 43 Dolla, A., Fournier, M. & Dermoun, Z. Oxygen defense in sulfate-reducing bacteria. *J*
549 *Biotechnol* **126**, 87–100, doi:10.1016/j.jbiotec.2006.03.041 (2006).
- 550 44 Houzen, H., Kano, T., Kondo, K., Takahashi, T. & Niino, M. The prevalence and incidence
551 of multiple sclerosis over the past 20 years in northern Japan. *Mult Scler Relat Disord* **73**,
552 104696, doi:10.1016/j.msard.2023.104696 (2023).
- 553

554 **METHODS**

555 **Ethics approval and consent to participate**

556 This study was approved by the National Center of Neurology and Psychiatry (NCNP) Ethics
557 Committee (A2016-132 and A2021-116) and the Research Ethics Committee of RIKEN Center for
558 Integrative Medical Sciences (RIKEN-Y-2022-030 and RIKEN-Y-2022-096). Signed informed
559 consent was obtained from all participants who provided specimens.

560

561 **Participants**

562 In total, 77 patients with MS and 29 HC participants were included. See **Extended data Table 7 and**
563 **Extended data Table 8** for clinical phenotypes of all the participants. Patients were recruited
564 through a MS clinic at the NCNP (Tokyo, Japan). Inclusion criteria required that participants in the
565 MS groups fulfilled the McDonald's criteria for diagnosis⁴⁵ and had MS-specific brain MRI lesions.
566 Exclusion criteria for MS and control participants included the presence of infectious diseases and
567 the usage of antibiotics during the collection of faecal samples. Among the 77 patients with MS,
568 RRMS was defined based on a relapsing-remitting clinical course, whereas SPMS was diagnosed
569 retrospectively by an attending physician based on the establishment of a sustained period of
570 worsening neurological impairments⁴⁶. No patients had an active relapse at the time of study
571 enrolment. The clinical severity of the patients was evaluated using the EDSS score which is a
572 measure of neurological impairment based on clinical assessment of MS⁴⁷. Samples from 77 patients
573 with MS were previously subjected to the metagenomic analysis¹.

574

575 **MRI analysis**

576 Imaging was performed on a 3-T MR system (Philips, Best, The Netherlands, or Siemens, Munich,
577 Germany). We measured total brain volume, grey matter volume, and white matter volume from 3D-
578 T1WI using FreeSurfer 6.0 (<http://surfer.nmr.mgh.harvard.edu/>), and total T2 lesion volume from
579 3D-T1WI and 3D-FLAIR using LST toolbox version 3.0.0 ([https://www.statistical-](https://www.statistical-modelling.de/lst.html)
580 [modelling.de/lst.html](https://www.statistical-modelling.de/lst.html)). This analysis included 60 of 77 patients with MS who received brain MRI
581 within 1 year before or after the faecal sampling.

582

583 **Faecal DNA preparation**

584 In accordance with a previously described method⁴⁸, freshly collected human faecal samples were
585 transported at 4 °C to the laboratory in a plastic bag containing a disposable oxygen-absorbing and
586 carbon dioxide-generating agent in which anaerobes sensitive to oxygen can survive. In the
587 laboratory, the faecal samples were suspended in phosphate-buffered saline containing 20% glycerol,
588 immediately frozen using liquid nitrogen and stored at -80 °C until use. Freshly collected mouse
589 faecal samples were immediately frozen using liquid nitrogen and stored at -80 °C until use.
590 Bacterial DNA was isolated and purified from the faecal samples according to enzymatic lysis
591 methods⁴⁸.

592

593 **qPCR analysis for faecal samples**

594 The DNA yield was assessed using Qubit dsDNA HS Assay Kits and a Qubit 3.0 or 4.0 fluorometer
595 (Thermo Fisher Scientific Inc., USA). Bacterial DNA was quantified using the Applied
596 Biosystems™ StepOnePlus™ Real-time quantitative PCR system (Thermo Fisher Scientific Inc.,
597 USA) and universal primers for the 16S rRNA gene V1-V2 region 27Fmod (5'-agrgttgatymtggtcag-
598 3') and 338R (5'-tgctgcctcgtaggagt-3'). The *Escherichia coli* 16S rRNA gene sequence was used as
599 standard. Fast PCR proceeded using Fast SYBR® Green Master Mix (Thermo Fisher Scientific Inc.,
600 USA) as described by the manufacturer.

601

602 **Metagenomic sequencing and data analysis**

603 The metagenomic shotgun library from patients with MS was prepared using the ThruPLEX DNA-
604 Seq kit (TaKaRa Bio. Inc., Japan) from 50 ng metagenomic DNA according to the manufacturer's
605 protocol. The metagenomic shotgun library from healthy participants was prepared using the Accel-
606 NGS 1S Plus DNA (Swift Bioscience) from 250ng metagenomic DNA according to the
607 manufacturer's protocol. After quantifying the prepared DNA library with the Kapa Library
608 Quantification Kit (Illumina, Inc., USA), sequencing was performed using the NovaSeq 6000
609 sequencing system with the 150bp paired-end mode (Illumina, Inc., USA). For sequences of the
610 ACCEL library, the first 15bp of Read 2 was trimmed. Quality filtering of the metagenomic
611 sequences was performed using fastp (v0.20.0)⁴⁹ and ParDRe (v2.1.5)⁵⁰ to remove low-quality reads

612 (length <50bp and mean QV <20) and duplicated reads, respectively. PhiX and human reads were
613 excluded by mapping the quality-filtered reads to the phiX and human genomes (hg38) using
614 minimap2⁵¹ with short-read mapping option (v2.13-r850). Taxonomic profiles were obtained using
615 mOTU profiler (v3.0.1)⁵² using 10 million reads per sample. Numbers in parentheses next to the
616 species names indicate the corresponding mOTU ID. Metagenomic assembly was performed using
617 metaSPAdes with default parameters (v3.14.0)⁵³. Metagenome-assembled genomes (MAGs) were
618 constructed using MetaBAT2 with default parameters (v2.11.2)⁵⁴. The quality of the MAGs was
619 assessed using CheckM (v1.1.3)⁵⁵ and GUNC (v1.0.5)⁵⁶, selecting high-quality (HQ) MAGs with
620 estimated completeness $\geq 90\%$, contamination $\leq 5\%$, and strain heterogeneity $\leq 0.5\%$, and passing
621 GUNC filtering. Representative HQ MAGs were selected by dereplicating the MAGs using dRep
622 (v3.2.2)⁵⁷ with 99% identity and 90% coverage. The ANI between HQ MAGs and complete
623 genomes of *T.nexilis* were calculated by pyani with the ANIm option⁵⁸.

624

625 **Long-read sequencing**

626 For the metagenomic Pacific Biosciences (PacBio) Sequel II sequencing (PacBio, Inc., USA),
627 SMRTbell libraries were constructed from 5 μg faecal metagenomic DNA according to the
628 manufacturer's protocol (Part Number 101-853-100 Version 05). Isolated bacterial DNA was
629 obtained from 20 ml of the cultured medium by the same DNA preparation method for faecal
630 samples. For the PacBio Sequel II multiplex sequencing of isolated bacteria, SMRTbell libraries
631 were constructed from 1 μg DNA according to the manufacturer's protocol (Part Number 101-696-
632 100 Version 02). HiFi reads were generated using CCS with --min-passes 3 and --min-rq 0.95
633 parameters (<https://github.com/PacificBiosciences/ccs>).

634

635 **Long-read metagenomic assembly**

636 The HiFi reads were assembled using hiCanu (v2.1.1)⁵⁹ with minReadLength=1500,
637 minOverlapLength=1500, genomeSize=100m, maxInputCoverage=100000, minInputCoverage=1,
638 stopOnLowCoverage=1, and -pacbio-hifi options. The circular contigs were detected by a terminal
639 direct repeat with $>95\%$ identity and $>1,000\text{bp}$ alignment length using minimap2. The HQ genome
640 satisfying completeness $\geq 90\%$, contamination $\leq 5\%$, and GUNC filtering were selected from circular

641 contigs. The ORFs of the HQ genomes were aligned to 20 bacterial marker genes of the *T.nexilis*
642 mOTU (ref_mOTU_v3_03689), and HQ *T.nexilis* genomes were determined, satisfying >96.5%
643 average nucleotide similarity of the marker genes. We successfully constructed a closed circular
644 genome of *T.nexilis* strain A3, B2, and B3 using this strategy (**Extended data Fig.4a**). In the
645 assembly of *T.nexilis* strain A2, we could not identify *T.nexilis* HQ genome from circular contigs.
646 Then, short reads were mapped to long-read contigs, and binning was performed using MetaBAT2.
647 The HQ bins were identified with the same criteria as those for the circular contigs and identified as
648 the HQ bins of the *T.nexilis* satisfying >96.5% average nucleotide similarity of the 20 bacterial
649 marker genes of the ref_mOTU_v3_03689. The phylogenetic tree of the 120 bacterial marker genes
650 determined using GTDB-Tk indicated that *T.nexilis*_strain A2 HQ bins were classified into cluster
651 A. Therefore, reference-guided assembly was performed to construct a closed circular genome of the
652 strain A2. The metagenomic HiFi reads were mapped to the strain A2 HQ bin and the strain A1
653 complete genome with >99% identity and >80% coverage. The mapped reads were assembled using
654 hifiasm_meta (v0.13)⁶⁰ with default parameters and the *T.nexilis* strain A2 closed circular genome
655 was obtained, satisfying the criteria for curating HQ genomes (**Extended data Fig.4b**).

656

657 **Long-read assembly of the isolated genomes**

658 The HiFi reads were assembled by hiCanu with minReadLength=5000, minOverlapLength=5000,
659 genomeSize=4m, and -pacbio-hifi options. The circular contigs were detected by a terminal direct
660 repeat with >95% identity and >1,000bp alignment length using minimap2. The genomic quality of
661 the circular contigs was assessed by CheckM and GUNC, and high-quality genome satisfying
662 completeness $\geq 95\%$, contamination $\leq 5\%$, and passing GUNC filtering were selected. The lack of the
663 MGEs in the short-read MAGs compared with the complete genome obtained by long-read was
664 visualised by Gview⁶¹.

665

666 **Abundance and prevalence of the *Tyzzarella nexilis* strains**

667 The bacterial marker genes were predicted by fetchMG from strain A and B MAGs⁵². The 11 genes
668 with <97% nucleotide similarity between strain A and B MAGs were selected as marker genes
669 specific to each MAG (**Extended data Table 3**). The RPM and prevalence were obtained by

670 mapping short reads to the concatenated sequence of 11 marker genes using Bowtie2 with 100%
671 identity and >10% covered fraction⁶².

672

673 **Comparative genomics of the *Tyzzarella nexilis* strains**

674 The ORFs of each *T.nexilis* genome were predicted using prokka⁶³ with default parameters (v1.13.3).

675 The visualisation of the complete genomes was performed by Proksee⁶⁴. The ORFs were aligned to
676 the eggNOG database (v5.0.2) using eggNOG mapper (ultra-sensitive mode) (v2.1.5)⁶⁵ with e-value

677 <1e-10, and assigned K number was mapped to the KEGG pathway using the KEGG mapper⁶⁶. The

678 ORFs were aligned to the comprehensive virulence factor database (VFDB)⁶⁷ (download date

679 2022/01/14) using DIAMOND blastp (v2.0.11) (sensitive mode) with e-value <1e-20 for the

680 annotation of the virulent genes. The ORFs were aligned to the prokaryotic virus remote homologous

681 groups (PHROGs) (version 4)⁶⁸ using DIAMOND blastp (v2.0.11) (sensitive mode) with >70%

682 identity and >50% coverage for the annotation of the phage-related genes. The 16S rRNA gene was

683 predicted using RNAmmer (v1.2) with default parameter⁶⁹, and the similarity of that among the

684 *T.nexilis* genomes was obtained from alignments using BLASTN. ICE-related genes were annotated

685 by the alignment between the ORFs and ICEberg database (last update version: May 2, 2018)⁷⁰ using

686 DIAMOND blastp (sensitive mode) with >50% identity and coverage. The insertion sequences were

687 predicted using the ISEscan (v1.7.2.3)⁷¹ with default parameters. The ICE signature genes were

688 determined using the ICEScreen (v1.2.0)⁷² with default parameters. The number of ICE in each

689 genome was counted for the complete ICE which had all ICE signature genes determined using the

690 ICEScreen. The defence system was predicted using the defense finder (v1.2.2)⁷³ with default

691 parameters. The publicly available *T.nexilis* genomes were obtained from the Genbank database and

692 genomes satisfying completeness $\geq 90\%$ and contamination $\leq 5\%$ (CheckM) were used for the

693 comparison. The multiple alignment of the 120 bacterial marker genes of the *T.nexilis* genomes was

694 performed using GDTB-Tk with default parameters. The phylogenetic tree was constructed using the

695 maximum likelihood method using MEGA X⁷⁴. The dotplot for comparing the genomic structures

696 was obtained using Gepard⁷⁵. To compare the number of MGEs of the *T.nexilis* genomes with those

697 of other Firmicutes genomes, we downloaded representative complete genomes from the GenBank

698 database (Release 255).

699 **Genomic analysis related to the horizontal gene transfer of the sulphur metabolic genes and**
700 **flagellar genes**

701 The genomic region including sulphur metabolic genes of the *T.nexilis*_strain B1 (780,456 –
702 822,674) was aligned to genome sequences from human gut isolates²⁹ with >99% nucleotide
703 similarity and >2kb alignment length using BLASTN and found significant alignments with
704 *R.gnavus*_strain AF33-12 (GCA_003475365.1). The *fliC* genes in the gut bacteria were obtained
705 from the HumGut database⁷⁶. The ORFs of the HumGut bacterial genomes were predicted by
706 prodigal (v2.6.3)⁷⁷ and aligned to the eggNOG database (v5.0.2) using eggNOG mapper (ultra-
707 sensitive mode) (v2.1.5) with e-value <1e-10 and assigned K number. The K02406 (*fliC*) annotated
708 genes were assigned as flagellin, and short (<300aa) or long genes (>600aa) were excluded from
709 further analysis. The multiple alignment of the *fliC* genes from the *T.nexilis*_strain B1 and HumGut
710 was obtained by mafft (v7.310)⁷⁸ with default parameters. The multiple alignment based on the 120
711 bacterial marker genes, including the *T.nexilis*_strain B1 and Firmicutes genomes of the HumGut,
712 was constructed by GDTB-tk with default parameters. The phylogenetic trees of the *fliC* gene and
713 120 bacterial marker genes were constructed by FastTree (v2.1.10)⁷⁹ with default parameters. The
714 visualisation of the phylogenetic tree was performed by iTOL⁸⁰. The conserved region between the
715 *T.nexilis*_strain B1 and B2 genomes neighbouring the flagellar gene cluster was identified by the
716 alignment using BLASTN with >95% similarity and >10kb alignment length. Direct repeats at the
717 edge of the composite transposon and ICE were manually identified. The abundance of *fliC* genes of
718 strain B1 was calculated as RPM using short-read mapping by BLASTX with >80% identity and
719 >50% coverage.

720

721 **Mice**

722 Germ-free (GF) C57BL/6 mice were originally purchased from CLEA Japan and bred in the GF
723 facility of the NCNP. We used female mice because MS is more common in females⁴⁴. Mice were
724 randomly divided into groups. No statistical estimations were performed to determine sample size.
725 The experiments were not randomised, and investigators were not blinded to allocation during
726 experiments and outcome assessment.

727

728 **Bacteria**

729 All faecal samples were homogenised and diluted with phosphate-buffered saline (PBS) containing
730 20% glycerol and then stored at -80 °C for the subsequent bacterial isolation. To isolate both
731 *T.nexilis*_strain A1 and B1, the cryopreserved faecal dilutions were plated on Eggerth Gagnon agar
732 plates and incubated under anaerobic conditions (80% N₂, 10% H₂, and 10% CO₂) in an anaerobic
733 chamber (Coy Laboratory Products) at 37 °C for two or four days. The 16S rRNA genes from
734 individual colonies were amplified using the 27F and 1492R primers. Then, Sanger sequencing was
735 conducted with the 27F and 519R primers to determine the colonies corresponding to *T.nexilis*_strain
736 A1 and B1. These bacteria were grown in YCFA liquid media and stored in 20% glycerol at -80 °C.
737

738 **Gnotobiotic experiments**

739 After 18 h of anaerobic culture for *T.nexilis*_strain A1 or B1 using YCFA liquid media at 37 °C, 200
740 µl of the media containing the same number of bacteria by turbidity measurement were orally
741 administered to female GF C57BL/6 mice at 5-7 weeks of age. Colonisation of bacteria was
742 confirmed by qPCR of faecal samples one week after the last administration (above mentioned).
743 Control GF mice were gavaged with culture media. The same procedure of bacterial administration
744 was repeated in one week. All gnotobiotic mice were kept in isolators for 2 weeks after the initial
745 administration and used for experiments.
746

747 **EAE induction**

748 For EAE induction, mice were injected subcutaneously at two sites on the back with 200 mg MOG₃₅₋
749 ₅₅ peptide (synthesised by Toray Research Center, Tokyo, Japan) and 1 mg heat-killed
750 *Mycobacterium tuberculosis* H37RA emulsified in complete Freund's adjuvant (Difco, KS, USA).
751 Four hundred nanograms of Pertussis toxin (List Biological Laboratories, CA, USA) were injected
752 intraperitoneally on days 0 and 2 after immunisation. EAE was clinically scored daily (0, no clinical
753 signs; 0.5, tail weakness; 1, partial tail paralysis; 1.5, severe tail paralysis; 2, flaccid tail; 2.5, flaccid
754 tail and hind limb weakness; 3, partial hind limb paralysis; 4, total hind limb paralysis; 5, hind and
755 foreleg paralysis). The mice given a score of 5 were immediately euthanised.
756

757 **Preparation of lymphocytes**

758 The isolation of intestinal lamina propria lymphocytes was performed as previously described⁸¹.
759 Briefly, the intestines were incubated in Hank's balanced salt solution (HBSS) supplemented with
760 2% foetal bovine serum (FBS), 1 mM dithiothreitol and 20 mM ethylenediamine tetraacetic acid
761 (EDTA) for 30 min at 37 °C with agitation. Then, the epithelial layer was removed by vigorous
762 shaking in HBSS. The remaining tissues were minced and incubated in Roswell Park Memorial
763 Institute (RPMI) 1640 supplemented with 2% FBS, 400 U/ml collagenase D (Roche), 0.25 U/ml
764 dispase (BD Biosciences) and 0.1mg/ml DNase I (Wako) for 30 min at 37 °C with agitation. The
765 digested tissues were suspended in 37% Percoll (GE Healthcare) and overlaid onto 70% Percoll
766 followed by centrifugation at 800 × g for 20 min. Lymphocytes at the interface were collected. To
767 isolate lymphocytes from the CNS, murine tissues from the mice were minced and incubated in
768 RPMI1640 supplemented with 2% FBS, 1.33 mg/ml collagenase H (Roche) and 20 µg/ml of DNase I
769 (Wako) for 45 min at 37 °C with agitation. Lymphocytes were collected from the 37% and 70%
770 Percoll interphase.

771

772 **Flow cytometry**

773 For intracellular cytokine staining, the cells were stimulated with 25 ng/ml phorbol myristate acetate
774 (PMA; Sigma) and 1 µg ionomycin (Sigma) in the presence of GoldiStop (BD Biosciences) for 4 h at
775 37 °C. Dead cells were stained with Zombie Aqua dye (BioLegend). After Fc receptors were blocked
776 with anti-CD16/32 (BD Biosciences), the cells were stained with anti-CD3 (BioLegend), anti-CD4
777 (eBioscience), anti-CD8 (BioLegend), anti-IL-17A (BioLegend), anti-IFN-γ (BioLegend), anti-
778 RORγt (BD Biosciences), and anti-FOXP3 (BioLegend) antibodies. All data were collected on a
779 FACS Canto II cytometer (BD Biosciences) and analysed using Flowjo (v.10.8, Tree Star).

780

781 **Th17 cell differentiation from naïve CD4⁺ T cells**

782 Naïve CD4⁺ T cells were prepared from splenocyte suspensions using a CD4⁺ T cells isolation kit
783 according to the manufacturer's instructions (Miltenyi Biotec) with an AutoMACS Pro Instrument
784 (Miltenyi Biotec) followed by flow cytometric sorting of TCRβ⁺CD4⁺CD25⁻CD62L^{high}CD44^{low} cells.
785 The 96-well flat bottom plates were coated with 20 mg/ml anti-hamster IgG at 37°C in PBS for 4 h

786 before washing with PBS and blocking with complete media. Approximately 2.5×10^4 naïve CD4⁺ T
787 cells were added per well and stimulated with anti-CD3 (Biolegend) and anti-CD28 (Biolegend)
788 antibodies in the presence of the combinations of recombinant cytokines: condition 1, 20 ng/ml IL-6
789 (Biolegend) and 2.5 ng/ml TGF- β (R&D Systems); condition 2, 20 ng/ml IL-6 and 5 μ g/ml SAA1
790 (R&D Systems). Supernatants were collected at 96 h, and the concentrations of IL-17 (R&D
791 Systems) and GM-CSF (BD Biosciences) were assessed using enzyme-linked immunosorbent assay
792 (ELISA).

793

794 **Coculture with lamina propria dendritic cells**

795 FACS-sorted CD11c^{high}CD11b^{high} lamina propria dendritic cells (5×10^3) were cultured in the
796 presence of heat-inactivated (60 °C 30 min) bacterial culture media (*T.nexilis*_strain A1 or B1) with
797 or without 1 μ M TLR5 antagonist (TH1020; MedChemExpress). Supernatants were collected at 18 h
798 and the concentration of IL-6 was assessed by ELISA (BD Biosciences).

799

800 **Isolation of colonic ECs**

801 The harvested colon was cut open longitudinally and washed well with PBS. Tissues were incubated
802 with 5mM EDTA in HBSS at 37 °C for 30 min with shaking to facilitate dissociation of ECs from
803 the lamina propria. ECs were collected by centrifugation, supplemented with RNAProtect Cell
804 Reagent (QIAGEN) and stored at -80 °C.

805

806 **RNA-seq analysis of colonic epithelial cells**

807 Total RNA was extracted from the colonic ECs using the RNeasy mini kit (Qiagen). Total RNA
808 concentration was calculated using Quant-IT RiboGreen (Invitrogen). To assess the integrity of the
809 total RNA, samples were run on the TapeStation RNA screentape (Agilent). Only HQ RNA
810 preparations were used for RNA library construction. A library was independently prepared with 1
811 μ g of total RNA for each sample using the Illumina TruSeq Stranded mRNA Sample Prep Kit
812 (Illumina, Inc., USA). The first step in the workflow involved purifying the poly-A-containing
813 mRNA molecules using poly-T-attached magnetic beads. Following purification, the mRNA was
814 fragmented into small pieces using divalent cations under elevated temperatures. The cleaved RNA

815 fragments were copied into first-strand cDNAs using SuperScript II reverse transcriptase
816 (Invitrogen) and random primers. This was followed by second-strand cDNA synthesis using DNA
817 polymerase I, RNase H, and dUTP. These cDNA fragments were then subjected to an end repair
818 process, the addition of a single “A” base, and then ligation of the adapters. The products were then
819 purified and enriched with PCR to create the final cDNA library. The libraries were quantified using
820 Kapa Library Quantification kits for Illumina Sequencing platforms according to the qPCR
821 Quantification Protocol Guide (Illumina) and qualified using the TapeStation D1000 ScreenTape
822 (Agilent). Indexed libraries were then submitted to an Illumina NovaSeq (Illumina, Inc.), and the
823 paired-end (2×100 bp) sequencing was performed by Macrogen Incorporated. The raw reads from
824 the sequencer were preprocessed to remove low-quality reads and the adapter sequence before
825 analysis, and the processed reads were aligned to the *Mus musculus (mm10)* using HISAT (v2.1.0)⁸².
826 HISAT utilises two types of indexes for alignment (a global, whole-genome index and tens of
827 thousands of small local indexes). Both types of indexes are constructed using the same Burrows–
828 Wheeler transform (BWT) and graph FM index (GFM) as those of Bowtie2. Because of its use of
829 these efficient data structures and algorithms, HISAT generates spliced alignments several times
830 faster than Bowtie and BWA, which are widely used. The reference genome sequence of *Mus*
831 *musculus (mm10)* and annotation data were downloaded from the UCSC table browser
832 (<http://genome.uscs.edu>). After alignment, StringTie was used to assemble aligned reads into
833 transcripts and to estimate their abundance^{83 84}. It provides the relative abundance estimates as read
834 count values of the transcript and gene expressed in each sample. Additionally, transcript assembly
835 of known transcripts, novel transcripts, and alternative splicing transcripts was processed using
836 StringTie. Based on that result, transcript and gene expression abundances were calculated as read
837 counts or fragments per kilobase of exon per million mapped reads (FPKM) value per sample. Gene-
838 enrichment and functional annotation analyses for significant gene lists were performed based on
839 gProfiler (<https://biit.cs.ut.ee/gprofiler/orth>).

840

841 **qPCR analysis for colonic ECs**

842 Total RNA was extracted from the colonic ECs using the RNeasy mini kit (Qiagen), and cDNA was
843 obtained with PrimeScriptTM RT Master Mix (TaKaRa). qPCR was performed using SYBR Premix

844 Ex Taq (TaKaRa) on a Thermal Cycler Dice Real Time System (TaKaRa). The following primer
845 pairs were used: *GAPDH*, 5'-GTCGTGGAGTCTACTGGTGTCTTC-3' and 5'-
846 GTCATATTTCTCGTGGTTCACACC-3'; *SAAI*, 5'- TG TTCACGAGGCTTTCCAAG-3' and 5'-
847 CCCGAGCATGGAAGTATTTG-3'.

848

849 **SEM**

850 After the removal of intestinal contents, the large intestine tissues were washed well with PBS and
851 fixed in 2.5% glutaraldehyde in 50 mM phosphate (pH 7.2). The plate-cultured bacterial colony was
852 also fixed in 2.5% glutaraldehyde in 50 mM phosphate (pH 7.2). The samples were post-fixed in 1%
853 osmium tetroxide in 50 mM phosphate buffer (pH 7.2) and dehydrated with increasing ethanol
854 concentrations. After dehydration, the samples were point-dried using carbon dioxide (EMCPD300,
855 Leica), coated with platinum (intestinal tissue) or osmium (cultured bacteria), and observed under a
856 scanning electron microscope (SU8240; Hitachi High-Technologies).

857

858 **TLR5 reporter HEK293 cell assay**

859 After 18 h anaerobic culture for *T.nexilis*_strain A1 or strain B1 using YCFA liquid media at 37 °C
860 with negative control just containing media, the samples were prepared. The TLR5-simulating
861 capacity was assessed using HEK-Blue™ mTLR5 cells (InvivoGen) and heat-inactivated (60 °C 30
862 min) bacterial culture media, following the manufacturer's protocol.

863

864 **Validation of bacterial signatures with public data**

865 We obtained publicly available metagenomic data (iMSMS: ERP115476; IBD: IBDMDB website
866 [<https://ibdmdb.org>]; rheumatoid arthritis: PRJEB6997; colorectal cancer: PRJEB10878; Parkinson's
867 disease: PRJNA834801) and clinical information from the cohorts of iMSMS³, IBD¹⁸, rheumatoid
868 arthritis¹⁹, colorectal cancer²⁰, and Parkinson's disease²¹ as validation cohorts. We analysed 1,139
869 samples (435 patients with RRMS, 133 patients with progressive MS, and 571 HCs) whose sequence
870 depth of metagenomic reads pooled based on sample ID exceeded one million reads in the iMSMS
871 cohort. We also analysed 104 samples (26 non-IBD individuals, 29 patients with ulcerative colitis,
872 and 49 patients with Crohn's disease), 141 samples (80 HCs and 61 patients with rheumatoid

873 arthritis), 126 samples (53 HCs and 73 patients with colorectal cancer), and 725 samples (234 HCs
874 and 491 patients with Parkinson's disease) whose sequence depth of metagenomic reads exceeded 10
875 million reads in these cohorts. Taxonomic profiles were performed with mOTU profiler (v3.0.1) to
876 compare with our original data.

877

878 **Sulphur metabolomics**

879 The freshly collected faecal samples were frozen and stored at -80°C until use. Sulphur metabolomic
880 analyses were outsourced to Sulphur Index service (Tokyo), Japan, with liquid chromatography
881 coupled to a tandem mass spectrometry (LC-MS/MS) system as described previously⁸⁵. Briefly, the
882 sulphur-containing compounds in the samples were extracted by adding methanol and were converted
883 to fluorescent derivatives with monobromobimane. The target metabolite levels were determined from
884 the peak area by mass chromatography and were represented as relative amounts after normalisation
885 with the peak area of the internal standard (D-camphor-10-sulphonic acid). In the process of data
886 analysis, we added 0.0001 (<the lowest value) to all values of glutathione and glutathione disulphides
887 to calculate the ratio of glutathione-to-glutathione disulphides because glutathione disulphides were
888 not detected in several samples from GF mice.

889

890 **Measurement of H₂S production**

891 After 48 h of anaerobic culture for YCFA liquid media (1ml) supplemented with *T.nexilis*_strain A1
892 or B1 with the same number of bacteria by turbidity measurement in a sealed 50ml conical tube at
893 37°C , the concentration of H₂S in the gas phase above the liquid phase was semi-quantitatively
894 assessed by lead acetate paper (Supelco) attached to the inner wall of the tube.

895

896 **Statistical analysis**

897 All statistical analyses were conducted with R version 4.2.0 or GraphPad Prism version 9.3.1. To
898 compare two groups of data, statistical differences were evaluated using the two-tailed unpaired *t*-test
899 (for normally distributed variables) or the two-tailed unpaired Wilcoxon rank-sum test (non-normally
900 distributed variables). MaAsLin2¹⁷ was used to compare the microbiome data between participant
901 groups. Differences between more than three groups were evaluated using one-way ANOVA

902 followed by Tukey's multiple comparisons test (for normally distributed variables) or the Kruskal-
903 Wallis test followed by Dunn's multiple comparison test (for non-normally distributed variables).
904 Spearman's rank correlation coefficient and MaAsLin2¹⁷ were used in the correlation analysis. The
905 chi-square test was used to compare the patient demographic data. The significance level was set at
906 p -value < 0.05.

907

908 **Data availability**

909 The short-read metagenomic sequences from 77 patients with MS and 29 HCs analysed in the
910 present study will be deposited in DDBJ/GenBank/EMBL before publication. The long-read
911 metagenomic sequences from 3 patients with MS will be also deposited in DDBJ/GenBank/EMBL
912 before publication. The closed circular genomic sequences from seven *T.nexilis* strains (DSM1787,
913 A1, A2, A3, B1, B2, and B3) will be deposited in DDBJ/GenBank/EMBL before publication.

914

915 **ACKNOWLEDGMENTS**

916 The authors thank M. Hattori for providing the research environment and supporting the projects.
917 The authors thank C. Shindo, N. Kumar, Z. Iioka, Y. Hattori, H. Yamaguchi, A. Kimura, and H.
918 Morita for technical support. The authors thank A. Tomita, D. Noto, M. Nakamura, N. Chihara, T.
919 Matsuoka, and R. Ikeguchi for obtaining informed patient consent and collecting samples. The
920 authors thank H. Sasaki, R. Sato, and M. Sato for supporting the electron microscopic imaging
921 analysis. The authors thank I. Ohtsu for analysing sulphur metabolomics in the faecal samples. The
922 authors thank RIKEN-IMS Genome Platform for high-throughput sequencing. This study was
923 supported by the Practical Research Project for Rare/Intractable Diseases from Japan Agency for
924 Medical Research and Development, AMED (19ek0109417h0001, 20ek0109417h0002,
925 21ek0109417h0003) and AMED-CREST (18gm1010011h0001, 19gm1010011h0002,
926 20gm1010011h0003, 21gm1010011h0004, 22gm1010011h0005, and 23gm1010011h0006).

927

928 **AUTHOR CONTRIBUTIONS**

929 D.Takewaki, Y.Kiguchi, W.Suda, and T.Yamamura planned the study. D.Takewaki, W.Sato,
930 S.Miyake, and T.Yamamura contributed to the collection of samples and clinical data. Y.Kiguchi,
931 H.Masuoka, Y.Ogata, R.Kurokawa, and W.Suda contributed to the collection and analysis of the
932 primary sequence data of faecal samples. D.Takewaki, Y.Kiguchi., and H.Masuoka mainly
933 conducted the metagenomic analysis. D.Takewaki, H.Masuoka, and S.Narushima isolated the
934 bacteria. D.Takewaki, H.Masuoka, S.Narushima, Y.Ozawa., S.Yagishita, T.Araki, and T.Yamamura
935 contributed to the gnotobiotic animal experiments. D.Takewaki, M.Manu, and B.Raveney conducted
936 immunological experiments. Y.Kimura and N.Sato conducted brain MRI analyses. D.Takewaki and
937 Y.Kiguchi wrote the first draft. W.Suda and T.Yamamura contributed to the completion of the
938 manuscript. All authors read, critically revised for important intellectual contents, and approved the
939 final manuscript.

940

941 **COMPETING INTERESTS**

942 D.Takewaki received support for research from Yakult Bio-Science Foundation. W. Sato received
943 support for clinical trials from Chugai Pharmaceutical Co., Ltd. and Biogen Japan Ltd. T. Yamamura

944 served on the scientific advisory board of Biogen Japan Ltd. and received support for research and
945 clinical trials from Sanofi K.K., Chugai Pharmaceutical Co., Ltd., UCB Japan Co., Ltd., Biogen
946 Japan Ltd., Chiome Bioscience Inc., Novartis Pharma K.K., and Mebix, Inc.

947

948 **EXTENDED DATA**

949 **Extended data Fig.1. Universality and specificity in the association between *Tyzzarella nexilis***
950 **and progressive MS**

951 (a-e) The relative abundance of *T.nexilis* (id03689) among the HC, RRMS, and SPMS (or
952 progressive MS) groups in our original (a: Japan) and iMSMS cohorts (b: United States, c: United
953 Kingdom, d: Argentina, e: untreated). (f) mOTU analysis using the publicly available and original
954 metagenomic data. The 40 mOTUs whose relative abundance was significantly enriched or depleted
955 in the SPMS group relative to healthy control (HC) group are shown ($p < 0.05$ and $|\text{coefficient}| > 1$).
956 We compared the abundance of these 40 mOTUs between the HC and other disease groups,
957 including RRMS (571 HCs and 435 patients)³, IBD (26 non-IBD individuals, 29 patients with
958 ulcerative colitis, and 49 patients with Crohn's disease)¹⁸, rheumatoid arthritis (80 HCs and 61
959 patients)¹⁹, colorectal cancer (53 HCs and 73 patients)²⁰, and Parkinson's disease (234 HCs and 491
960 patients)²¹. A coefficient value based on MaAsLin2 in a comparison between the disease and healthy
961 groups is depicted from the lowest (blue) to the highest (red) according to the scale shown on the
962 right. Data are presented as mean \pm S.D. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; MaAsLin2.

963

964 **Extended data Fig.2. Associations between microbial abundance and a clinical severity score**

965 (a-b) The relative abundance of four mOTUs at each EDSS score separately in the original (n = 77)
966 and iMSMS (n = 568) cohorts of patients with MS. The four mOTUs were selected as the species
967 whose relative abundance was the most positively correlated with an EDSS score other than
968 *Tyzzarella nexilis* (id03689) based on a coefficient value of MaAsLin2 among 40 mOTUs that were
969 highly enriched or depleted in the original SPMS group compared with the HC group. Curve fitting
970 using non-linear regression for the average of the relative abundance in each group was conducted:
971 the non-linear curves are shown in red.

972

973 **Extended data Fig.3. Correlation between microbial abundance and quantitative brain MRI**
974 **parameters**

975 (a) Among the 77 patients with MS, 60 patients who underwent brain MRI within 1 year before or
976 after the faecal sampling were included in this analysis, and the brain MRI parameters between

977 patients with RRMS (n=48) and SPMS (n=12) were compared. (b) The 40 mOTUs whose relative
978 abundance was significantly enriched or depleted in the SPMS group compared with the HC group
979 are shown ($p < 0.05$ and $|\text{coefficient}| > 1$). We analysed the correlation between the abundance of
980 these 40 mOTUs and four brain MRI parameters including total brain volume, grey matter volume,
981 white matter volume, and total T2 lesion volume among 60 patients with MS. The Spearman
982 coefficient R in the correlation between the relative abundance of each mOTU and brain MRI
983 parameters is depicted from the lowest (purple) to the highest (orange) according to the scale shown
984 on the right. $*p < 0.05$, $**p < 0.01$; Wilcoxon rank-sum test (a), Spearman's rank correlation
985 coefficient (b).

986

987 **Extended data Fig.4. Workflow of the long-read metagenomic assembly**

988 (a) Workflow for constructing the *Tyzzarella nexilis* genome from closed circular contigs. The strain
989 A3, B2, and B3 genomes were constructed using this strategy. First, the metagenomic HiFi reads
990 were assembled by hiCanu. Then, the high-quality (HQ) chromosomal contigs were selected by
991 CheckM and GUNC from circular contigs. Finally, HQ genomes having marker genes of *T.nexilis*
992 (ref_mOTU_v3_03689) with $>96.5\%$ identity were selected. (b) Workflow for combinational
993 analysis of long-read metagenomic assembly, binning, and reference-guided assembly. The
994 *T.nexilis*_strain A2 genome was constructed using this strategy. The metagenomic short reads were
995 mapped to the linear contigs obtained by metagenomic assembly using HiFi reads. Then, the binning
996 analysis and quality check of bins were performed by metabat2 and CheckM, respectively. The
997 marker genes of *T.nexilis* (ref_mOTU_v3_03689) were aligned to HQ-bins and obtained HQ-bin of
998 *T.nexilis* (cluster A) consisting of three contigs. For collecting *T.nexilis*-related HiFi reads, all
999 metagenomic HiFi reads were mapped to the HQ-bin of *T.nexilis* and the complete genome of strain
1000 A1. Finally, *T.nexilis*-related HiFi reads were assembled by hifiasm_meta and obtained a closed
1001 circular genome of the *T.nexilis*_strain A2. (a,b) Details of these workflows are described in the
1002 Method section.

1003

1004

1005 **Extended data Fig.5 Comparisons of the genomic structures between MS patients-derived**
1006 ***Tyzzarella nexilis* strains**

1007 Dot plot diagram for genomic similarity among the six genomes of *T.nexilis*_strain A1, A2, A3, B1,
1008 B2, and B3.

1009

1010 **Extended data Fig.6. The genomic comparison between short-read MAG and complete genome**
1011 **in *Tyzzarella nexilis*_strain B1**

1012 Comparison of genomic structures between the short-read MAG and the isolation-based complete
1013 genome of mobile genetic elements (MGEs)-enriched *T.nexilis*_strain B1. The predicted regions of
1014 integrative and conjugative elements (ICE), insertion sequences (IS), and prophages are shown.

1015 Black arrows indicate the specific regions predicted as MGEs among the missing regions in short-
1016 read MAGs.

1017

1018 **Extended data Fig 7. Functional analysis in the comparison between *Tyzzarella nexilis* strains**

1019 (a) Quantification of 16S rRNA gene copies in the faeces of GF and *T.nexilis*_strain A1 or B1 mono-
1020 colonised mice (n=3 mice). (b) Representative FACS plots (gated on CD3⁺CD4⁺CD8⁻).

1021 Frequency of regulatory T cells in the small intestine (n=5 mice), large intestine (n=5 mice), and

1022 central nervous system (GF, n=13; *T.nexilis*_strain A1 and B1, n=11). (d-f) Gene expression profile

1023 of colonic ECs between *T.nexilis*_strain B1 mono-colonised mice (n=4), *T.nexilis*_strain A1 mono-

1024 colonised mice (n=4), and germ-free (GF) mice (n=4). Differential gene expression in the colonic

1025 ECs was analysed by RNA-seq. (d) Gene ontology (GO) terms significantly enriched in up-regulated

1026 gene sets in the colonic ECs derived from the strain B1 mono-colonised mice compared with those

1027 from the strain A1 mono-colonised mice are shown. (e) Comparison of the genes annotated to α -

1028 defensin between the GF, strain A1 mono-colonised, and strain B1 mono-colonised mice. The z-

1029 score based on the transcripts per kilobase million (TPM) is depicted from the lowest (blue) to the

1030 highest (red) according to the scale shown on the right. (f) TPM of *SAA1* between the GF, strain A1

1031 mono-colonised, and strain B1 mono-colonised mice. (g) The presence or absence of KEGG

1032 orthologies (KOs) included in strain B1, but not in strain A1 in each module within the cationic

1033 antimicrobial peptide resistance (map01503). Data are presented as mean \pm S.D. ns $p > 0.05$, * p

1034 <0.05, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, two-sided unpaired t-test (c), one-way ANOVA
1035 with Tukey's multiple comparisons test (f).

1036

1037 **Extended data Fig.8. Genome comparisons among seven *Tyzzarella nexilis* strains**

1038 The presence or absence of KEGG orthologies (KOs) included in flagellar assembly, sulphur
1039 metabolism, and CAMP resistance pathways within the genomes of *T.nexilis*_DSM1787, strain A1,
1040 A2, A3, B1, B2, and B3.

1041

1042 **Extended data Fig.9. Phylogeny of the *fliC* genes**

1043 Phylogenetic tree of the *fliC* genes from *T.nexilis*_strain B1 and the HumGut database. Each branch
1044 colour shows the phylum of the genomes encoding *fliC* genes.

1045

1046 **Extended data Fig.10. The nature and functions of bacteria associated with multiple sclerosis
1047 progression**

1048 Mobile genetic elements (MGEs)-enriched *T.nexilis* strains are abundant in the gut of patients with
1049 SPMS. Some of the strains acquired pathogenic genes associated with flagella formation and
1050 sulphate reduction via horizontal gene transfer from another microorganism. These strains-derived
1051 flagella potentially induce pathogenic Th17 cells via the combination of TLR5 stimulation and
1052 promotion of adherence to colonic ECs. These T cells might migrate into the CNS and accelerate
1053 neuroinflammation. The sulphate reduction accompanied by hydrogen sulphide (H₂S) production is
1054 potentially associated with neurodegeneration. The depletion of defence systems and subsequent
1055 enrichment of MGEs might have shaped the pathogenic bacteria underlying MS progression.

1056 Abbreviations: IS = insertion sequence; ICE = integrative conjugative element; TLR5 = toll-like
1057 receptor 5; SAA1 = serum amyloid A1; CAMP; cationic antimicrobial peptide resistance.

1058

1059 **Extended data Table 1. Sequence statistics of the NovaSeq and Sequel sequencers**

1060 The number of filter-passed* NovaSeq reads and total bases of filter-passed* NovaSeq reads are
1061 presented. The number of Sequel HiFi reads, total bases of Sequel HiFi reads, and average reads
1062 length are also presented.

1063

1064 **Extended data Table 2. Significantly enriched or depleted mOTUs in SPMS compared with**
1065 **RRMS**

1066 The 38 mOTUs whose relative abundance was significantly enriched or depleted in the SPMS group
1067 compared with the RRMS group are presented in the descending order of coefficient value of
1068 MaAsLin2. mOTUs whose coefficient value >0 are SPMS-enriched mOTUs and those whose
1069 coefficient value <0 are RRMS-enriched mOTUs.

1070

1071 **Extended data Table 3. Strain-specific marker genes of *Tyzzarella nexilis*_strain A or B MAG**

1072 The list of 11 bacterial marker genes for calculating *T.nexilis*_strain A and B MAGs are shown. All
1073 genes have <97% nucleotide similarity between strain A and B MAGs.

1074

1075 **Extended data Table 4. The number of mobile genetic elements in seven *Tyzzarella nexilis***
1076 **strains and 726 representative Firmicutes strains**

1077 Seven *T.nexilis* genomes used in the present study and 726 representative complete genomes
1078 assigned to Firmicutes in the GenBank database were analysed. The number of MGEs including
1079 insertion sequences (IS), integrative and conjugative elements (ICE), and prophages are presented.

1080

1081 **Extended data Table 5. 16S rRNA gene similarity between the genomes of seven *Tyzzarella***
1082 ***nexilis* strains**

1083 Similarity of nucleotide sequences in full-length 16S rRNA genes between the seven *T.nexilis*
1084 genomes.

1085

1086 **Extended data Table 6. Gene annotations of *Tyzzarella nexilis*_strain B1**

1087 Gene annotations of the *T.nexilis*_strain B1 genome. Gene annotations based on Pfam, KEGG
1088 orthologies, and ICE-related genes are shown.

1089

1090

1091

1092 **Extended data Table 7. Demographics and characteristics of the patients and controls**

1093 Sixty-two patients with RRMS, 15 patients with SPMS, and 29 healthy controls were recruited. Data
1094 are represented as mean \pm SEM. Abbreviations: BMI = body mass index; ARR = annual relapse rate;
1095 EDSS = expanded disability status scale; PSL = prednisolone; IS = immunosuppressive drugs;
1096 DMDs; disease-modifying drugs; IFN- β = interferon- β ; GA = glatiramer acetate; FTY = fingolimod;
1097 NTZ = natalizumab; DMF = dimethyl fumarate; HC = healthy control; RRMS = relapsing-remitting
1098 multiple sclerosis; SPMS = secondary progressive multiple sclerosis.

1099

1100 **Extended data Table 8. Clinical information of patients and controls**

1101 Detailed clinical information including recruitment site, ethnicity, age, sex, body mass index (BMI),
1102 year of onset, disease duration, treatments, and EDSS score is presented.

1103

1104 **METHOD REFERENCES**

- 1105 45 Thompson, A. J. *et al.* Diagnosis of multiple sclerosis: 2017 revisions of the McDonald
1106 criteria. *Lancet Neurol* **17**, 162-173, doi:10.1016/s1474-4422(17)30470-2 (2018).
- 1107 46 Rovaris, M. *et al.* Secondary progressive multiple sclerosis: current knowledge and future
1108 challenges. *Lancet Neurol* **5**, 343-354, doi:10.1016/s1474-4422(06)70410-0 (2006).
- 1109 47 Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability
1110 status scale (EDSS). *Neurology* **33**, 1444-1452 (1983).
- 1111 48 Kim, S. W. *et al.* Robustness of gut microbiota of healthy adults in response to probiotic
1112 intervention revealed by high-throughput pyrosequencing. *DNA research : an international*
1113 *journal for rapid publication of reports on genes and genomes* **20**, 241-253,
1114 doi:10.1093/dnares/dst006 (2013).
- 1115 49 Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor.
1116 *Bioinformatics* **34**, i884-i890, doi:10.1093/bioinformatics/bty560 (2018).
- 1117 50 González-Domínguez, J. & Schmidt, B. ParDRe: faster parallel duplicated reads removal tool
1118 for sequencing studies. *Bioinformatics* **32**, 1562-1564, doi:10.1093/bioinformatics/btw038
1119 (2016).
- 1120 51 Li, H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* **34**, 3094-
1121 3100, doi:10.1093/bioinformatics/bty191 (2018).
- 1122 52 Milanese, A. *et al.* Microbial abundance, activity and population genomic profiling with
1123 mOTUs2. *Nat Commun* **10**, 1014, doi:10.1038/s41467-019-08844-4 (2019).
- 1124 53 Nurk, S., Meleshko, D., Korobeynikov, A. & Pevzner, P. A. metaSPAdes: a new versatile
1125 metagenomic assembler. *Genome research* **27**, 824-834, doi:10.1101/gr.213959.116 (2017).
- 1126 54 Kang, D. D. *et al.* MetaBAT 2: an adaptive binning algorithm for robust and efficient genome
1127 reconstruction from metagenome assemblies. *PeerJ* **7**, e7359, doi:10.7717/peerj.7359 (2019).
- 1128 55 Parks, D. H., Imelfort, M., Skennerton, C. T., Hugenholtz, P. & Tyson, G. W. CheckM:
1129 assessing the quality of microbial genomes recovered from isolates, single cells, and
1130 metagenomes. *Genome research* **25**, 1043-1055, doi:10.1101/gr.186072.114 (2015).
- 1131 56 Orakov, A. *et al.* GUNC: detection of chimerism and contamination in prokaryotic genomes.
1132 *Genome biology* **22**, 178, doi:10.1186/s13059-021-02393-0 (2021).

- 1133 57 Olm, M. R., Brown, C. T., Brooks, B. & Banfield, J. F. dRep: a tool for fast and accurate
1134 genomic comparisons that enables improved genome recovery from metagenomes through
1135 de-replication. *Isme j* **11**, 2864-2868, doi:10.1038/ismej.2017.126 (2017).
- 1136 58 Pritchard, L., Glover, R. H., Humphris, S., Elphinstone, J. G. & Toth, I. K. Genomics and
1137 taxonomy in diagnostics for food security: soft-rotting enterobacterial plant pathogens.
1138 *Analytical Methods* **8**, 12-24, doi:10.1039/c5ay02550h (2016).
- 1139 59 Nurk, S. *et al.* HiCanu: accurate assembly of segmental duplications, satellites, and allelic
1140 variants from high-fidelity long reads. *Genome research* **30**, 1291-1305,
1141 doi:10.1101/gr.263566.120 (2020).
- 1142 60 Feng, X., Cheng, H., Portik, D. & Li, H. Metagenome assembly of high-fidelity long reads
1143 with hifiasm-meta. *Nature methods* **19**, 671-674, doi:10.1038/s41592-022-01478-3 (2022).
- 1144 61 Petkau, A., Stuart-Edwards, M., Stothard, P. & Van Domselaar, G. Interactive microbial
1145 genome visualization with GView. *Bioinformatics* **26**, 3125-3126,
1146 doi:10.1093/bioinformatics/btq588 (2010).
- 1147 62 Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nature methods*
1148 **9**, 357-359, doi:10.1038/nmeth.1923 (2012).
- 1149 63 Seemann, T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* **30**, 2068-2069,
1150 doi:10.1093/bioinformatics/btu153 (2014).
- 1151 64 Grant, J. R. *et al.* Proksee: in-depth characterization and visualization of bacterial genomes.
1152 *Nucleic Acids Res* **51**, W484-w492, doi:10.1093/nar/gkad326 (2023).
- 1153 65 Cantalapiedra, C. P., Hernández-Plaza, A., Letunic, I., Bork, P. & Huerta-Cepas, J. eggNOG-
1154 mapper v2: Functional Annotation, Orthology Assignments, and Domain Prediction at the
1155 Metagenomic Scale. *Mol Biol Evol* **38**, 5825-5829, doi:10.1093/molbev/msab293 (2021).
- 1156 66 Kanehisa, M. & Sato, Y. KEGG Mapper for inferring cellular functions from protein
1157 sequences. *Protein Sci* **29**, 28-35, doi:10.1002/pro.3711 (2020).
- 1158 67 Liu, B., Zheng, D., Zhou, S., Chen, L. & Yang, J. VFDB 2022: a general classification
1159 scheme for bacterial virulence factors. *Nucleic Acids Res* **50**, D912-d917,
1160 doi:10.1093/nar/gkab1107 (2022).

1161 68 Terzian, P. *et al.* PHROG: families of prokaryotic virus proteins clustered using remote
1162 homology. *NAR Genom Bioinform* **3**, lqab067, doi:10.1093/nargab/lqab067 (2021).

1163 69 Lagesen, K. *et al.* RNAmmer: consistent and rapid annotation of ribosomal RNA genes.
1164 *Nucleic Acids Res* **35**, 3100-3108, doi:10.1093/nar/gkm160 (2007).

1165 70 Liu, M. *et al.* ICEberg 2.0: an updated database of bacterial integrative and conjugative
1166 elements. *Nucleic Acids Research* **47**, D660-D665, doi:10.1093/nar/gky1123 (2018).

1167 71 Xie, Z. & Tang, H. ISEScan: automated identification of insertion sequence elements in
1168 prokaryotic genomes. *Bioinformatics* **33**, 3340-3347, doi:10.1093/bioinformatics/btx433
1169 (2017).

1170 72 Lao, J. *et al.* ICEscreen: a tool to detect Firmicute ICEs and IMEs, isolated or enclosed in
1171 composite structures. *NAR Genom Bioinform* **4**, lqac079, doi:10.1093/nargab/lqac079 (2022).

1172 73 Tesson, F. *et al.* Systematic and quantitative view of the antiviral arsenal of prokaryotes. *Nat*
1173 *Commun* **13**, 2561, doi:10.1038/s41467-022-30269-9 (2022).

1174 74 Stecher, G., Tamura, K. & Kumar, S. Molecular Evolutionary Genetics Analysis (MEGA) for
1175 macOS. *Mol Biol Evol* **37**, 1237-1239, doi:10.1093/molbev/msz312 (2020).

1176 75 Krumsiek, J., Arnold, R. & Rattei, T. Gepard: a rapid and sensitive tool for creating dotplots
1177 on genome scale. *Bioinformatics* **23**, 1026-1028, doi:10.1093/bioinformatics/btm039 (2007).

1178 76 Hiseni, P., Rudi, K., Wilson, R. C., Hegge, F. T. & Snipen, L. HumGut: a comprehensive
1179 human gut prokaryotic genomes collection filtered by metagenome data. *Microbiome* **9**, 165,
1180 doi:10.1186/s40168-021-01114-w (2021).

1181 77 Hyatt, D. *et al.* Prodigal: prokaryotic gene recognition and translation initiation site
1182 identification. *BMC bioinformatics* **11**, 119, doi:10.1186/1471-2105-11-119 (2010).

1183 78 Katoh, K., Misawa, K., Kuma, K. & Miyata, T. MAFFT: a novel method for rapid multiple
1184 sequence alignment based on fast Fourier transform. *Nucleic Acids Res* **30**, 3059-3066,
1185 doi:10.1093/nar/gkf436 (2002).

1186 79 Price, M. N., Dehal, P. S. & Arkin, A. P. FastTree: computing large minimum evolution trees
1187 with profiles instead of a distance matrix. *Mol Biol Evol* **26**, 1641-1650,
1188 doi:10.1093/molbev/msp077 (2009).

1189 80 Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL) v4: recent updates and new
1190 developments. *Nucleic Acids Res* **47**, W256-w259, doi:10.1093/nar/gkz239 (2019).

1191 81 Furusawa, Y. *et al.* Commensal microbe-derived butyrate induces the differentiation of
1192 colonic regulatory T cells. *Nature* **504**, 446-450, doi:10.1038/nature12721 (2013).

1193 82 Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory
1194 requirements. *Nature methods* **12**, 357-360, doi:10.1038/nmeth.3317 (2015).

1195 83 Pertea, M., Kim, D., Pertea, G. M., Leek, J. T. & Salzberg, S. L. Transcript-level expression
1196 analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. *Nat Protoc* **11**,
1197 1650-1667, doi:10.1038/nprot.2016.095 (2016).

1198 84 Pertea, M. *et al.* StringTie enables improved reconstruction of a transcriptome from RNA-seq
1199 reads. *Nat Biotechnol* **33**, 290-295, doi:10.1038/nbt.3122 (2015).

1200 85 Kawano, Y. *et al.* Involvement of the *yciW* gene in l-cysteine and l-methionine metabolism
1201 in *Escherichia coli*. *J Biosci Bioeng* **119**, 310-313, doi:10.1016/j.jbiosc.2014.08.012 (2015).

Figure 1




Fig. Identification of gut bacteria associated with MS progression

(a) The coefficient value based on MaAsLin2 and $-\log_{10}$ p -value obtained from the comparison between the 62 patients with RRMS and 15 patients with SPMS are shown in the volcano plot. (b) Global microbiome alterations in progressive MS compared with HC. SPMS-enriched or depleted ($p < 0.05$ and $|\text{coefficient}| > 1$) mOTUs are shown in the left column. The differences of these SPMS-enriched or depleted mOTUs in the comparison between the progressive MS and HC groups in each country using the validation cohort of international MS microbiome study (iMSMS) are shown. A coefficient value based on MaAsLin2 in the comparison between the disease and healthy groups is depicted from the lowest (blue) to the highest (red) according to the scale shown on the right. The coefficient values based on MaAsLin2 in the correlation between the relative abundance of each mOTU and an expanded disability scale (EDSS) score in the original and iMSMS cohorts are depicted from the lowest (purple) to the highest (orange) according to the scale shown on the right. (c) The relative abundance of *Tyzzerella nexilis* (id03689) at each EDSS score separately in the original ($n = 77$) and iMSMS ($n = 568$) cohorts of patients with MS. The non-linear regression curves for the average of the relative abundance in each EDSS group are shown in red. (d-e) Number of mapped reads per million (RPM) to the 11 strain-specific marker genes between *T. nexilis*_strain A and B MAGs (d) and their prevalence (e) among the 29 HCs, 62 patients with RRMS, and 15 patients with SPMS. Data are presented as the mean \pm S.D. ns $p > 0.05$, * $p < 0.05$; MaAsLin2.

Figure 2




Fig.2. Genome comparison among various *Tyzzarella nexilis* strains

(a) Schematic representation of the strategy for construction of complete *T.nexilis* genomes. Five faecal samples derived from patients with RRMS and SPMS were selected as sources of *T.nexilis* strains. Closed circular genomes were obtained from two isolated strains (*T.nexilis_strain A1* and *B1*) and from four non-isolated strains (*T.nexilis_strain A2*, *A3*, *B2*, and *B3*). The structure of the six closed circular *T.nexilis* genomes is shown. The average nucleotide identity (ANI) between *T.nexilis_strain A* MAG (or strain B MAG) and the obtained *T.nexilis* genomes is shown. (b) Phylogenetic tree of the short-read MAGs, seven closed circular genomes, and publicly available 12 genomes of *T.nexilis* based on 120 bacterial marker genes. (c) Comparisons of the various genomic characteristics among various *T.nexilis* genomes [number of total genes, number of virulent genes in VFDB, number of insertion sequence (IS)/ prophage/ integrative and conjugative elements (ICE), and number of defence system]. The presence or absence of anti-MGE defence systems including Abortive infection (Abi), CRISPR-Cas9, DISARM, Gao, Hachiman, Restriction modification (RM), and Wadjet is also shown. The z-score based on the number of genes is depicted from the lowest (blue) to the highest (red) according to the scale shown on the right. (d) Comparisons of the number of mobile genetic elements among the 727 representative Firmicutes genomes in the GenBank and seven *T.nexilis* strains.

Figure 3




Fig.3. Functional characteristics of *Tyzzerella nexilis* strains

(a) Schematic of the experimental flow. (b) EAE score of germ-free (GF) mice inoculated with *T.nexilis_strain A1* or B1.

Combined results of two independent experiments are shown (GF, n=13; strain A1 and B1, n=11). (c) Representative FACS plots (gated on CD3⁺CD4⁺CD8⁻). (d) Frequency of Th17 cells in the small intestine (n=5 mice), large intestine (n=5 mice), and central nervous system (GF, n=13; strain A1 and B1, n=11). (e) Differences of gene contents between strain A1 and B1 based on KEGG pathways. (f) Co-culture of heat-inactivated strains with TLR5 reporter HEK cells. (g) SEM images of cultured strains. A flagella-like structure is indicated by an arrow. (h) Co-culture of heat-inactivated strains with CD11c^{high}CD11b^{high} intestinal dendritic cells. (i) SEM images on the surface of the colon in the mono-colonised mice. (j) Gene expression of *SAA1* on the colonic epithelial cells was assessed by qPCR. (k, l) The assay for Th17 cell differentiation. The concentrations of IL-17 (k) and GM-CSF (l) were assessed by ELISA. (m) Number of mapped reads per million (RPM) to *fliC* genes of *T.nexilis_strain B1* among the 29 HCs, 62 RRMS, and 15 SPMS patients. (n) The presence or absence of KEGG orthologies (KOs) included in strain B1 but not in strain A1 in each module within sulphur metabolism (map00920). (o) The ratio of glutathione to glutathione disulphide in the faeces of GF and strain A1 or B1 mono-colonised mice (n=3 mice). (p) The production of hydrogen sulphide (H₂S) in YCFA liquid culture media was assessed by lead acetate paper. Data are presented as the mean ± S.D. ns $p > 0.05$, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$; Kruskal-Wallis test with Dunn's multiple comparisons test (b, m), two-sided unpaired t-test (d, k, l), one-way ANOVA with Tukey's multiple comparisons test (f, h, j, o).

Figure 4




Fig.4. Acquisition mechanism of potentially pathogenic genes

(a) Genomic comparison between *Tyzzereella nexilis*_strain B1 and *Ruminococcus gnavus*_strain AF33-12. The ORF annotations of sulphur metabolic genes and phage-aligned sulphur metabolic genes are shown coloured in red and blue, respectively. Grey connections indicate conserved regions between two genomes. (b) Phylogenetic tree of the Firmicutes genomes encoding *fliC* genes from the *T.nexilis*_strain B1 and HumGut based on 120 bacterial marker genes. Each colour shows the order of each genome. (c) Phylogenetic tree of the *fliC* genes from *T.nexilis*_strain B1 and HumGut database in five orders in Firmicutes. Each branch colour shows the order of the genomes encoding *fliC* genes. (d) Genomic comparison between *T.nexilis*_strain B1 (with flagellar genes) and B2 (without flagellar genes). The ORF annotations of flagellar genes, ICE-related genes, and ICE signature genes are shown coloured in red, blue, and brown, respectively. Insertion sequence (IS) regions are shown as blue boxes. The name of each IS indicates a family of IS and IS new means a novel family of IS. Grey connections indicate conserved regions between two genomes. The direct terminal repeat sequences and the coordinate at the edge of ICE and composite transposon including flagellar genes are shown with dashed lines of blue and black, respectively.

Extended data


Figure 1

Extended data Fig.1. Universality and specificity in the association between *Tyzzzeria nexilis* and progressive MS

(a-e) The relative abundance of *T. nexilis* (id03689) among the HC, RRMS, and SPMS (or progressive MS) groups in our original (a: Japan) and iMSMS cohorts (b: United States, c: United Kingdom, d: Argentina, e: untreated). (f) mOTU analysis using the publicly available and original metagenomic data. The 40 mOTUs whose relative abundance was significantly enriched or depleted in the SPMS group relative to healthy control (HC) group are shown ($p < 0.05$ and $|\text{coefficient}| > 1$). We compared the abundance of these 40 mOTUs between the HC and other disease groups, including RRMS (571 HCs and 435 patients)³, IBD (26 non-IBD individuals, 29 patients with ulcerative colitis, and 49 patients with Crohn's disease)¹⁸, rheumatoid arthritis (80 HCs and 61 patients)¹⁹, colorectal cancer (53 HCs and 73 patients)²⁰, and Parkinson's disease (234 HCs and 491 patients)²¹. A coefficient value based on MaAsLin2 in a comparison between the disease and healthy groups is depicted from the lowest (blue) to the highest (red) according to the scale shown on the right. Data are presented as mean \pm S.D. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; MaAsLin2.

Extended data

Figure 2




Extended data Fig.2. Associations between microbial abundance and a clinical severity score

(a-b) The relative abundance of four mOTUs at each EDSS score separately in the original ($n = 77$) and iMSMS ($n = 568$) cohorts of patients with MS. The four mOTUs were selected as the species whose relative abundance was the most positively correlated with an EDSS score other than *Tyzzarella nexilis* (id03689) based on a coefficient value of MaAsLin2 among 40 mOTUs that were highly enriched or depleted in the original SPMS group compared with the HC group. Curve fitting using non-linear regression for the average of the relative abundance in each group was conducted: the non-linear curves are shown in red.

Extended data

Figure 3




Extended data Fig.3. Correlation between microbial abundance and quantitative brain MRI parameters

(a) Among the 77 patients with MS, 60 patients who underwent brain MRI within 1 year before or after the faecal sampling were included in this analysis, and the brain MRI parameters between patients with RRMS (n=48) and SPMS (n=12) were compared. (b) The 40 mOTUs whose relative abundance was significantly enriched or depleted in the SPMS group compared with the HC group are shown ($p < 0.05$ and $|\text{coefficient}| > 1$). We analysed the correlation between the abundance of these 40 mOTUs and four brain MRI parameters including total brain volume, grey matter volume, white matter volume, and total T2 lesion volume among 60 patients with MS. The Spearman coefficient R in the correlation between the relative abundance of each mOTU and brain MRI parameters is depicted from the lowest (purple) to the highest (orange) according to the scale shown on the right. * $p < 0.05$, ** $p < 0.01$; Wilcoxon rank-sum test (a), Spearman's rank correlation coefficient (b).

Extended data


Figure 4



Extended data Fig.4. Workflow of the long-read metagenomic assembly

(a) Workflow for constructing the *Tyzzzerella nexilis* genome from closed circular contigs. The strain A3, B2, and B3 genomes were constructed using this strategy. First, the metagenomic HiFi reads were assembled by hiCanu. Then, the high-quality (HQ) chromosomal contigs were selected by CheckM and GUNC from circular contigs. Finally, HQ genomes having marker genes of *T. nexilis* (ref_mOTU_v3_03689) with >96.5% identity were selected. (b) Workflow for combinational analysis of long-read metagenomic assembly, binning, and reference-guided assembly. The *T. nexilis*_strain A2 genome was constructed using this strategy. The metagenomic short reads were mapped to the linear contigs obtained by metagenomic assembly using HiFi reads. Then, the binning analysis and quality check of bins were performed by metabat2 and CheckM, respectively. The marker genes of *T. nexilis* (ref_mOTU_v3_03689) were aligned to HQ-bins and obtained HQ-bin of *T. nexilis* (cluster A) consisting of three contigs. For collecting *T. nexilis*-related HiFi reads, all metagenomic HiFi reads were mapped to the HQ-bin of *T. nexilis* and the complete genome of strain A1. Finally, *T. nexilis*-related HiFi reads were assembled by hifiasm_meta and obtained a closed circular genome of the *T. nexilis*_strain A2. (a,b) Details of these workflows are described in the Method section.

Extended data Figure 5




Extended data Fig.5 Comparisons of the genomic structures between MS patients-derived *Tyzzzerella nexilis* strains

Dot plot diagram for genomic similarity among the six genomes of *T. nexilis*_strain A1, A2, A3, B1, B2, and B3.

Extended data

Figure 6




Extended data Fig.6. The genomic comparison between short-read MAG and complete genome in *Tyzzerella nexilis*_strain B1

Comparison of genomic structures between the short-read MAG and the isolation-based complete genome of mobile genetic elements (MGEs)-enriched *T.nexilis*_strain B1. The predicted regions of integrative and conjugative elements (ICE), insertion sequences (IS), and prophages are shown. Black arrows indicate the specific regions predicted as MGEs among the missing regions in short-read MAGs.

Extended data

Figure 7




Extended data Fig 7. Functional analysis in the comparison between *Tyzzereella nexilis* strains

(a) Quantification of 16S rRNA gene copies in the faeces of GF and *T.nexilis_strain A1* or B1 mono-colonised mice (n=3 mice). (b) Representative FACS plots (gated on CD3⁺CD4⁺CD8⁻). (c) Frequency of regulatory T cells in the small intestine (n=5 mice), large intestine (n=5 mice), and central nervous system (GF, n=13; *T.nexilis_strain A1* and B1, n=11). (d-f) Gene expression profile of colonic ECs between *T.nexilis_strain B1* mono-colonised mice (n=4), *T.nexilis_strain A1* mono-colonised mice (n=4), and germ-free (GF) mice (n=4). Differential gene expression in the colonic ECs was analysed by RNA-seq. (d) Gene ontology (GO) terms significantly enriched in up-regulated gene sets in the colonic ECs derived from the strain B1 mono-colonised mice compared with those from the strain A1 mono-colonised mice are shown. (e) Comparison of the genes annotated to α -defensin between the GF, strain A1 mono-colonised, and strain B1 mono-colonised mice. The z-score based on the transcripts per kilobase million (TPM) is depicted from the lowest (blue) to the highest (red) according to the scale shown on the right. (f) TPM of *SAA1* between the GF, strain A1 mono-colonised, and strain B1 mono-colonised mice. (g) The presence or absence of KEGG orthologies (KOs) included in strain B1, but not in strain A1 in each module within the cationic antimicrobial peptide resistance (map01503). Data are presented as mean \pm S.D. ns $p > 0.05$, * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, two-sided unpaired t-test (c), one-way ANOVA with Tukey's multiple comparisons test (f).

Extended data

Figure 8




Extended data Fig.8. Genome comparisons among seven *Tyzzzerella nexilis* strains

The presence or absence of KEGG orthologies (KOs) included in flagellar assembly, sulphur metabolism, and CAMP resistance pathways within the genomes of *T.nexilis*_DSM1787, strain A1, A2, A3, B1, B2, and B3.

Extended data

Figure 9




Extended data Fig.9. Extended data Fig.9. Phylogeny of the *fliC* genes

Phylogenetic tree of the *fliC* genes from *T.nexilis_strain B1* and the HumGut database. Each branch colour shows the phylum of the genomes encoding *fliC* genes.

Extended data

Figure 10



Extended data Fig.10. The nature and functions of bacteria associated with multiple sclerosis progression

Mobile genetic elements (MGEs)-enriched *T. nexilis* strains are abundant in the gut of patients with SPMS. Some of the strains acquired pathogenic genes associated with flagella formation and sulphate reduction via horizontal gene transfer from another microorganism. These strains-derived flagella potentially induce pathogenic Th17 cells via the combination of TLR5 stimulation and promotion of adherence to colonic ECs. These T cells might migrate into the CNS and accelerate neuroinflammation. The sulphate reduction accompanied by hydrogen sulphide (H₂S) production is potentially associated with neurodegeneration. The depletion of defence systems and subsequent enrichment of MGEs might have shaped the pathogenic bacteria underlying MS progression. Abbreviations: IS = insertion sequence; ICE = integrative conjugative element; TLR5 = toll-like receptor 5; SAA1 = serum amyloid A1; CAMP; cationic antimicrobial peptide resistance.

Extended data

Table 1

Sample ID	NovaSeq reads		Sequel II HiFi reads		
	Number of filter-passed* NovaSeq reads	Total bases of filter-passed* NovaSeq reads	Number of HiFi reads	Total bases of HiFi reads	Average read length
RRMS_001	71,815,702	10,759,546,579	-	-	-
RRMS_002	77,212,788	11,276,617,433	-	-	-
RRMS_003	42,411,368	6,354,219,649	-	-	-
RRMS_004	90,684,058	13,291,269,220	2,252,056	21,906,770,313	9,728
RRMS_005	69,275,172	10,086,797,435	-	-	-
RRMS_006	93,470,332	13,606,048,815	-	-	-
RRMS_007	55,415,138	8,294,899,346	-	-	-
RRMS_008	92,992,880	13,569,374,061	-	-	-
RRMS_009	81,033,534	11,840,134,612	-	-	-
RRMS_010	102,303,182	15,017,651,121	-	-	-
RRMS_011	57,083,870	8,538,636,575	-	-	-
RRMS_012	93,579,296	13,705,678,362	-	-	-
RRMS_013	49,584,782	7,418,247,083	-	-	-
RRMS_014	103,614,988	15,235,318,747	-	-	-
RRMS_015	61,769,138	9,238,860,025	-	-	-
RRMS_016	90,892,678	13,251,336,823	-	-	-
RRMS_017	90,169,114	13,272,172,122	-	-	-
RRMS_018	46,891,090	6,910,676,861	-	-	-
RRMS_019	77,679,732	11,372,599,971	-	-	-
RRMS_020	67,240,518	10,067,186,534	-	-	-
RRMS_021	98,437,522	14,463,046,456	-	-	-
RRMS_022	75,115,786	10,935,224,611	-	-	-
RRMS_023	94,634,896	13,741,751,263	-	-	-
RRMS_024	132,708,216	19,164,322,098	-	-	-
RRMS_025	109,255,820	15,917,834,231	-	-	-
RRMS_026	118,125,228	17,300,266,035	-	-	-
RRMS_027	123,133,244	17,940,399,025	-	-	-
RRMS_028	109,324,824	16,038,893,762	-	-	-
RRMS_029	91,150,392	13,270,498,314	-	-	-
RRMS_030	112,992,168	16,446,970,975	-	-	-
RRMS_031	87,653,118	12,693,791,476	-	-	-
RRMS_032	122,371,928	17,737,830,230	-	-	-
RRMS_033	94,018,444	13,386,909,852	-	-	-
RRMS_034	117,753,716	17,276,602,266	-	-	-
RRMS_035	102,228,276	14,942,873,546	-	-	-
RRMS_036	105,936,266	15,369,346,740	-	-	-
RRMS_037	98,092,500	14,311,892,648	-	-	-
RRMS_038	101,113,704	14,706,895,320	-	-	-
RRMS_039	76,830,190	11,111,114,309	-	-	-
RRMS_040	131,033,768	18,959,733,016	-	-	-
RRMS_041	110,030,896	16,143,545,055	1,937,559	12,239,256,839	6,317
RRMS_042	105,098,422	15,450,738,757	-	-	-
RRMS_043	58,184,854	8,711,748,783	-	-	-
RRMS_044	60,586,618	9,074,941,882	-	-	-
RRMS_045	103,186,632	14,960,271,736	-	-	-
RRMS_046	69,209,394	10,048,106,871	-	-	-
RRMS_047	78,618,816	11,748,246,396	-	-	-
RRMS_048	52,444,362	7,851,478,352	-	-	-
RRMS_049	54,553,944	8,166,317,718	-	-	-
RRMS_050	78,726,224	11,525,290,192	-	-	-
RRMS_051	71,372,748	10,666,703,375	-	-	-
RRMS_052	59,867,710	8,972,625,582	-	-	-
RRMS_053	64,063,440	9,602,248,220	-	-	-
RRMS_054	76,736,138	11,501,419,834	-	-	-
RRMS_055	64,774,948	9,707,004,090	-	-	-
RRMS_056	66,236,162	9,926,776,944	-	-	-
RRMS_057	60,724,948	9,085,661,409	-	-	-
RRMS_058	63,462,548	9,508,821,816	-	-	-
RRMS_059	52,590,858	7,876,885,968	-	-	-
RRMS_060	96,292,072	14,422,753,663	-	-	-
RRMS_061	64,336,754	9,638,018,718	-	-	-
RRMS_062	48,487,890	7,170,509,056	-	-	-
SPMS_001	98,696,618	14,412,439,162	-	-	-
SPMS_002	510,636,458	72,943,520,736	-	-	-
SPMS_003	80,204,252	12,016,311,616	-	-	-
SPMS_004	160,763,816	23,534,667,107	-	-	-
SPMS_005	139,732,710	20,517,285,185	-	-	-
SPMS_006	130,558,414	19,124,788,380	-	-	-
SPMS_007	149,835,056	21,957,145,163	-	-	-
SPMS_008	95,678,020	13,981,977,760	-	-	-
SPMS_009	131,344,640	19,120,523,073	-	-	-
SPMS_010	107,307,636	15,777,110,378	-	-	-
SPMS_011	122,868,862	17,988,019,539	-	-	-
SPMS_012	56,839,782	8,518,499,041	-	-	-
SPMS_013	92,458,144	13,813,620,610	-	-	-
SPMS_014	84,293,450	12,629,972,863	-	-	-
SPMS_015	64,916,930	9,720,715,038	2,682,547	23,612,546,464	8,802
HC_001	67,181,110	9,568,348,321	-	-	-
HC_002	77,581,460	11,048,930,174	-	-	-
HC_003	94,454,542	13,453,045,642	-	-	-
HC_004	77,225,970	10,999,234,072	-	-	-
HC_005	35,756,698	5,056,701,513	-	-	-
HC_006	108,966,222	15,519,189,758	-	-	-
HC_007	80,646,890	11,485,685,988	-	-	-
HC_008	85,730,540	12,208,597,656	-	-	-
HC_009	67,179,748	9,566,623,711	-	-	-
HC_010	165,948,304	23,631,606,242	-	-	-
HC_011	52,041,532	7,411,948,141	-	-	-
HC_012	276,719,104	39,407,836,820	-	-	-
HC_013	57,390,380	8,173,117,823	-	-	-
HC_014	186,439,548	26,554,264,176	-	-	-
HC_015	181,631,782	25,868,425,465	-	-	-
HC_016	140,519,818	20,011,443,683	-	-	-
HC_017	61,192,772	8,714,773,151	-	-	-
HC_018	62,650,628	8,923,064,017	-	-	-
HC_019	72,644,758	10,346,655,497	-	-	-
HC_020	285,893,080	40,717,037,710	-	-	-
HC_021	50,380,976	7,175,419,517	-	-	-
HC_022	145,192,270	20,679,931,903	-	-	-
HC_023	175,358,410	24,975,573,815	-	-	-
HC_024	171,173,838	24,377,963,136	-	-	-
HC_025	162,077,852	23,082,260,866	-	-	-
HC_026	190,499,698	27,131,375,725	-	-	-
HC_027	199,526,250	28,416,204,905	-	-	-
HC_028	210,907,982	30,032,840,859	-	-	-
HC_029	213,885,590	30,459,990,817	-	-	-
Average	103,391,965	15,015,450,648	2,290,721	19,252,857,872	8,282
Max	510,636,458	72,943,520,736	2,682,547	23,612,546,464	9,728
Min	35,756,698	5,056,701,513	1,937,559	12,239,256,839	6,317
Total	10,959,548,274	1,591,637,768,718	6,872,162	57,758,573,616	24,847

* Filter-passed; quality filtered and unmapped reads with human genome

Extended data Table 1. Sequence statistics of the NovaSeq and Sequel sequencers

The number of filter-passed* NovaSeq reads and total bases of filter-passed* NovaSeq reads are presented. The number of Sequel HiFi reads, total bases of Sequel HiFi reads, and average reads length are also presented.

Extended data

Table 2

Taxonomy ID	coefficient value	p-value
<i>Tyzzarella nexilis</i> (id03689)	2.559	0.007
<i>Bifidobacterium</i> species incertae sedis (id26736)	2.193	0.001
<i>Alistipes putredinis</i> (id03683)	2.015	0.036
<i>Bacteroides coprocola</i> (id11279)	1.917	0.017
<i>Streptococcus salivarius</i> (id01350)	1.742	0.004
<i>Coprococcus</i> sp. (id01683)	1.656	0.014
<i>Bilophila wadsworthia</i> (id04300)	1.549	0.042
<i>Clostridium glycyrrhizinilyticum</i> (id03672)	1.427	0.006
<i>Parabacteroides distasonis</i> (id03640)	1.375	0.041
<i>Bacteroides</i> species incertae sedis (id17856)	1.299	0.007
<i>Clostridium</i> species incertae sedis (id17741)	1.283	0.017
uncultured <i>Eubacterium</i> sp. (id13063)	1.264	0.007
<i>Parabacteroides</i> species incertae sedis (id26659)	1.246	0.042
<i>Bacteroides</i> species incertae sedis (id17683)	1.200	0.042
<i>Hungatella hathewayi</i> (id03435)	1.161	0.014
<i>Clostridium citroniae</i> (id04828)	1.127	0.002
<i>Streptococcus anginosus</i> (id00567)	1.110	0.003
<i>Alistipes</i> species incertae sedis (id28774)	1.094	0.007
<i>Streptococcus</i> species incertae sedis (id28879)	1.007	0.007
<i>Gemella sanguinis</i> (id04303)	0.938	0.035
<i>Streptococcus gordonii</i> (id03970)	0.887	0.032
<i>Actinomyces</i> sp. ICM47 (id01914)	0.862	0.040
<i>Clostridium</i> sp. CAG:273 (id12673)	0.829	0.037
<i>Streptococcus</i> species incertae sedis (id26680)	0.787	0.026
<i>Streptococcus</i> species incertae sedis (id19491)	0.764	0.037
<i>Streptococcus oralis</i> (id00290)	0.704	0.007
Lachnospiraceae species incertae sedis (id18295)	0.684	0.026
<i>Solobacterium</i> species incertae sedis (id12387)	0.632	0.004
uncultured <i>Clostridium</i> sp. (id11611)	0.589	0.034
Erysipelotrichaceae species incertae sedis (id16196)	0.532	0.043
<i>Actinomyces marseillensis/pacaensis</i> (id03846)	0.487	0.042
<i>Streptococcus oralis</i> (id00292)	0.443	0.042
<i>Streptococcus pneumoniae</i> (id00282)	0.441	0.032
<i>Lachnoclostridium</i> species incertae sedis (id16281)	-0.528	0.026
uncultured <i>Eubacterium</i> sp. (id08868)	-0.536	0.047
<i>Bacteroides intestinalis</i> (id02809)	-0.888	0.038
<i>Bacteroides thetaiotaomicron</i> (id01657)	-1.441	0.048
<i>Faecalibacterium prausnitzii</i> (id06110)	-2.613	0.028

Extended data Table 2. Significantly enriched or depleted mOTUs in SPMS compared with RRMS

The 38 mOTUs whose relative abundance was significantly enriched or depleted in the SPMS group compared with the RRMS group are presented in the descending order of coefficient value of MaAsLin2. mOTUs whose coefficient value >0 are SPMS-enriched mOTUs and those whose coefficient value <0 are RRMS-enriched mOTUs.

Extended data

Table 3

Annotation	Nucleotide sequence similarity between strain A and B MAGs (%)
Ribosome-binding ATPase YchF	96.3
50S ribosomal protein L11	96.9
DNA-directed RNA polymerase subunit beta	93.5
50S ribosomal protein L3	83.5
30S ribosomal protein S8	95.3
50S ribosomal protein L15	96.4
Protein translocase subunit SecY	91.3
DNA-directed RNA polymerase subunit alpha	95.4
Cysteine--tRNA ligase	96.0
Leucine--tRNA ligase	96.5
Signal recognition particle receptor FtsY	96.2

Extended data Table 3. Strain-specific marker genes of *Tyzzarella nexilis*_strain A or B MAG

The list of 11 bacterial marker genes for calculating *T.nexilis*_strain A and B MAGs are shown. All genes have <97% nucleotide similarity between strain A and B MAGs.

Extended data

Table 4

Assembly accession	Taxonomy ID	Kingdom	Phylum	Class	Order	Family	Genus	Species	Number of IS	Number of ICE	Number of prophage
N/A	N/A	Bacteria	Firmicutes	Clostridia	Eubacteriales	Lachnospiraceae	Tyzzereella	Tyzzereella nexilis DSM1787	67	6	0
N/A	N/A	Bacteria	Firmicutes	Clostridia	Eubacteriales	Lachnospiraceae	Tyzzereella	Tyzzereella nexilis_strain A1	63	6	3
N/A	N/A	Bacteria	Firmicutes	Clostridia	Eubacteriales	Lachnospiraceae	Tyzzereella	Tyzzereella nexilis_strain A2	64	2	2
N/A	N/A	Bacteria	Firmicutes	Clostridia	Eubacteriales	Lachnospiraceae	Tyzzereella	Tyzzereella nexilis_strain A3	40	3	3
N/A	N/A	Bacteria	Firmicutes	Clostridia	Eubacteriales	Lachnospiraceae	Tyzzereella	Tyzzereella nexilis_strain B1	347	7	6
N/A	N/A	Bacteria	Firmicutes	Clostridia	Eubacteriales	Lachnospiraceae	Tyzzereella	Tyzzereella nexilis_strain B2	327	8	3
N/A	N/A	Bacteria	Firmicutes	Clostridia	Eubacteriales	Lachnospiraceae	Tyzzereella	Tyzzereella nexilis_strain B3	342	8	4
GCA_000007085.1	273068	Bacteria	Firmicutes	Clostridia	Thermoanaerobacterales	Thermoanaerobacteraceae	<i>Caldanaerobacter</i>	<i>Caldanaerobacter subterraneus</i>	73	0	0
GCA_000007625.1	212717	Bacteria	Firmicutes	Clostridia	Eubacteriales	Clostridiaceae	<i>Clostridium</i>	<i>Clostridium tetani</i>	23	0	3
GCA_000008445.1	261594	Bacteria	Firmicutes	Bacilli	Bacillales	Bacillaceae	<i>Bacillus</i>	<i>Bacillus cereus</i> group	16	0	4
GCA_000009785.1	235909	Bacteria	Firmicutes	Bacilli	Bacillales	Bacillaceae	<i>Geobacillus</i>	<i>Geobacillus thermoleovorans</i> group	97	0	2
GCA_000009905.1	292459	Bacteria	Firmicutes	Clostridia	Eubacteriales	Symbiobacteriaceae	<i>Symbiobacterium</i>	<i>Symbiobacterium thermophilum</i>	47	0	0
GCA_000010265.1	583346	Bacteria	Firmicutes	Clostridia	Eubacteriales	Clostridiaceae	<i>Clostridium</i>	<i>Clostridium kluveri</i>	50	2	3
GCA_000011245.1	221109	Bacteria	Firmicutes	Bacilli	Bacillales	Bacillaceae	<i>Oceanobacillus</i>	<i>Oceanobacillus iheyensis</i>	17	0	1
GCA_000012865.1	246194	Bacteria	Firmicutes	Clostridia	Thermoanaerobacterales	Thermoanaerobacteraceae	<i>Carboxydotherrmus</i>	<i>Carboxydotherrmus hydrogenoformans</i>	17	0	1
GCA_000014505.1	278197	Bacteria	Firmicutes	Bacilli	Lactobacillales	Lactobacillaceae	<i>Pediococcus</i>	<i>Pediococcus pentosaceus</i>	8	0	2

⋮

GCA_900638585.1	54006	Bacteria	Firmicutes	Tissierellia	Tissierellales	Peptoniphilaceae	<i>Peptoniphilus</i>	<i>Peptoniphilus ivorii</i>	8	0	0
GCA_901482605.1	1498	Bacteria	Firmicutes	Clostridia	Eubacteriales	Clostridiaceae	<i>Hathewayia</i>	<i>Hathewayia histolytica</i>	23	0	4
GCA_901544385.1	1302	Bacteria	Firmicutes	Bacilli	Lactobacillales	Streptococcaceae	<i>Streptococcus</i>	<i>Streptococcus gordonii</i>	7	0	0
GCA_901553735.1	1340	Bacteria	Firmicutes	Bacilli	Lactobacillales	Streptococcaceae	<i>Streptococcus</i>	<i>Streptococcus porcinus</i>	4	2	2
GCA_902387955.1	301301	Bacteria	Firmicutes	Clostridia	Eubacteriales	Lachnospiraceae	<i>Roseburia</i>	<i>Roseburia hominis</i>	23	4	0
GCA_902729405.1	1561005	Bacteria	Firmicutes	Clostridia	Eubacteriales	Peptococcaceae	<i>Acididesulfobacillus</i>	<i>Acididesulfobacillus acetoxydans</i>	103	0	0
GCA_903886475.1	1308	Bacteria	Firmicutes	Bacilli	Lactobacillales	Streptococcaceae	<i>Streptococcus</i>	<i>Streptococcus thermophilus</i>	62	0	0
GCA_940670685.1	2934315	Bacteria	Firmicutes	Clostridia	Eubacteriales	Lachnospiraceae	<i>Anaeropeptidivorans</i>	<i>Anaeropeptidivorans aminofermentans</i>	33	1	2
GCA_940677205.1	36835	Bacteria	Firmicutes	Clostridia	Eubacteriales	Lachnospiraceae	<i>Tyzzereella</i>	[<i>Clostridium</i>] <i>colinum</i>	11	0	5

※ Row 18 to 724 cannot be displayed due to lack of space. The complete version will be provided by Excel format.

Extended data Table 4. The number of mobile genetic elements in seven *Tyzzereella nexilis* strains and 726 representative Firmicutes strains

Seven *T. nexilis* genomes used in the present study and 726 representative complete genomes assigned to Firmicutes in the GenBank database were analysed. The number of MGEs including insertion sequences (IS), integrative and conjugative elements (ICE), and prophages are presented.

Extended data

Table 5

16S rRNA gene similarity (%)	<i>T.nexilis</i> _DSM1787	<i>T.nexilis</i> _strain A1	<i>T.nexilis</i> _strain A2	<i>T.nexilis</i> _strain A3	<i>T.nexilis</i> _strain B1	<i>T.nexilis</i> _strain B2	<i>T.nexilis</i> _strain B3
<i>T.nexilis</i> _DSM1787	-	99.934	99.868	98.947	99.474	99.539	99.539
<i>T.nexilis</i> _strain A1	99.934	-	99.934	98.881	99.474	99.539	99.539
<i>T.nexilis</i> _strain A2	99.868	99.934	-	98.815	99.408	99.474	99.474
<i>T.nexilis</i> _strain A3	98.947	98.881	98.815	-	98.421	98.487	98.487
<i>T.nexilis</i> _strain B1	99.474	99.474	99.408	98.421	-	99.934	99.737
<i>T.nexilis</i> _strain B2	99.539	99.539	99.474	98.487	99.934	-	99.803
<i>T.nexilis</i> _strain B3	99.539	99.539	99.474	98.487	99.737	99.803	-

Average similarity (%)	
cluster A - cluster A	99.40
cluster B - cluster B	99.83
cluster A - cluster B	99.24

Extended data Table 5. 16S rRNA gene similarity between the genomes of seven *Tyzzarella nexilis* strains

Similarity of nucleotide sequences in full-length 16S rRNA genes between the seven *T.nexilis* genomes.

Extended data

Table 6

Category	start	end	strand	Pfam	KEGG Orthology	ICEBerg annotation	Amino acid similarity with ICEBerg gene (%)	ICE signature genes predicted by ICEscreen
CDS	101	1,486	+	Bac_DnaA,Bac_DnaA_C,DnaA_N	K02313			
CDS	1,758	2,867	+	DNA_pol3_beta,DNA_pol3_beta_2,DNA_pol3_beta_3	K02338			
CDS	2,871	3,080	+	S4_2	K14761			
CDS	3,103	4,200	+	SMC_N	K03629			
CDS	4,211	6,127	+	DNA_gyraseB,DNA_gyraseB_C,HATPase_c,Toprim	K02470			
⋮								
CDS	797,240	798,175	+	PALP	K01738			
CDS	798,178	799,182	+	SBP_bac_11	K02048			
CDS	799,163	800,038	+	BPD_transp_1	K02046, K15496			
CDS	800,061	800,933	+	BPD_transp_1	K02047			
CDS	800,938	801,999	+	ABC_tran,TOBE_2	K02045, K02052			
CDS	802,024	803,736	+	FAD_binding_2,Succ_DH_flav_C	K00394			
CDS	803,720	804,034	+	Fer4,Fer4_9	K00395			
CDS	804,135	805,034	+	PAPS_reduct	K00390, K00957	ICEValHN437IGenBankIKT07277111..94290 Vibrio alginolyticus strain HN437 transposon integrating conjugative element ICEValHN437, complete sequence.	67	
CDS	805,036	806,673	+	APS_kinase,GTP_EFTU,GTP_EFTU_D2,GTP_EFTU_D3	K00955, K00956			
⋮								
CDS	3,517,457	3,520,501	+	Gram_pos_anchor		Tn6079IGenBankIGU9515381462..28872 Uncultured bacterium MID12 genomic sequence.	93	
CDS	3,520,740	3,521,066	+	DUF961		Tn6079IGenBankIGU9515381462..28872 Uncultured bacterium MID12 genomic sequence.	94	
CDS	3,521,082	3,521,465	+	DUF961		CTn7IGenBankIAM18035513938102..3963961 Clostridium difficile 630 complete genome.	95	
CDS	3,521,588	3,522,361	+					
CDS	3,522,438	3,522,965	+	GAD-like				
CDS	3,523,066	3,523,569	+					
CDS	3,523,609	3,524,436	+	DUF5037				
CDS	3,524,482	3,524,994	+					
CDS	3,525,037	3,525,621	+					
CDS	3,525,726	3,526,031	+	FtsK_SpoIIIE		Tn6194-likeGenBankIHG47534611..28014 [Clostridium] difficile Tn6194-like conjugative transposon, strain CI17.	95	
CDS	3,526,078	3,527,694	-	DDE_Tnp_IS66,DDE_Tnp_IS66_C,LZ_Tnp_IS66,zf-IS66				
CDS	3,528,113	3,529,150	-	Phage_int_SAM_1,Phage_int_SAM_4,Phage_int_SAM_5,Phage_integrase	K04763			
CDS	3,529,147	3,530,127	-	Phage_integrase				
CDS	3,530,124	3,531,347	-					
CDS	3,531,459	3,531,671	-	TnpB_IS66	K07484			
CDS	3,531,665	3,532,078	-	HTH_23,HTH_Tnp_1				
CDS	3,532,381	3,533,355	+	FtsK_SpoIIIE		Tn6194-likeGenBankIHG47534611..28014 [Clostridium] difficile Tn6194-like conjugative transposon, strain CI17.	98	Coupling protein
CDS	3,533,539	3,534,735	+	HTH_3,HTH_31,Rep_trans	K07467	Tn6194-likeGenBankIHG47534611..28014 [Clostridium] difficile Tn6194-like conjugative transposon, strain CI17.	100	Relaxase
CDS	3,534,748	3,534,882	+	DUF3789		CTn1IGenBankIAM1803551428851..453332 Clostridium difficile 630 complete genome.	75	
CDS	3,534,883	3,535,104	+			Tn6194-likeGenBankIHG47534611..28014 [Clostridium] difficile Tn6194-like conjugative transposon, strain CI17.	99	
CDS	3,535,181	3,535,654	+			CTnBSTIGenBankIAY34559511..100903 Bacteroides uniformis strain WH207 transposon CTnBST, complete sequence.	54	
CDS	3,535,756	3,536,052	+			CTn1IGenBankIAM1803551428851..453332 Clostridium difficile 630 complete genome.	92	
CDS	3,535,992	3,536,474	+	ArdA		CTn7IGenBankIAM18035513938102..3963961 Clostridium difficile 630 complete genome.	91	
CDS	3,536,492	3,536,995	+	ArdA		Tn6194-likeGenBankIHG47534611..28014 [Clostridium] difficile Tn6194-like conjugative transposon, strain CI17.	99	
CDS	3,537,114	3,537,512	+	TcpE		CTn7IGenBankIAM18035513938102..3963961 Clostridium difficile 630 complete genome.	99	
CDS	3,537,490	3,539,940	+	AAA_10		Tn5386IGenBankIDQ321786167..29238 Enterococcus faecium strain D344R transposon Tn5386, complete sequence.	97	VirB4
CDS	3,539,940	3,542,150	+			CTn1IGenBankIAM1803551428851..453332 Clostridium difficile 630 complete genome.	92	
CDS	3,542,147	3,543,154	+	Lysozyme_like,NLPC_P60		Tn6194-likeGenBankIHG47534611..28014 [Clostridium] difficile Tn6194-like conjugative transposon, strain CI17.	98	
CDS	3,543,171	3,544,082	+	TpcC		CTn1IGenBankIAM1803551428851..453332 Clostridium difficile 630 complete genome.	97	
CDS	3,544,261	3,545,118	+	Acetyltransf_1,Cass2,HTH_18				
CDS	3,545,111	3,545,488	+	MatE				
CDS	3,545,668	3,546,753	+	DDE_Tnp_1				
CDS	3,546,887	3,547,816	+	MatE				
CDS	3,547,813	3,548,037	+			CTn1IGenBankIAM1803551428851..453332 Clostridium difficile 630 complete genome.	93	
CDS	3,548,083	3,549,375	-	HATPase_c,HisKA				
CDS	3,549,369	3,550,055	-	Response_reg,Trans_reg_C				
CDS	3,550,249	3,550,743	+					
CDS	3,550,755	3,551,978	+	FtsX				
CDS	3,551,982	3,553,427	+	FtsX_MacB_PCD	K02004			
CDS	3,553,441	3,554,076	+	ABC_tran		CTn5IGenBankIAM18035512137789..2181291 Clostridium difficile 630 complete genome.	60	
CDS	3,554,471	3,554,791	+					
CDS	3,554,776	3,555,009	+	HTH_16		Tn6194-likeGenBankIHG47534611..28014 [Clostridium] difficile Tn6194-like conjugative transposon, strain CI17.	56	
CDS	3,555,323	3,555,526	+	Tn916-Xis		CTn1IGenBankIAM1803551428851..453332 Clostridium difficile 630 complete genome.	100	
CDS	3,555,605	3,556,795	+	Integrase_DNA,Phage_int_SAM_5,Phage_integrase		CTn1IGenBankIAM1803551428851..453332 Clostridium difficile 630 complete genome.	99	Tyrosine integrase
⋮								
CDS	4,286,634	4,286,846	-	Haemolytic	K08998			
CDS	4,286,850	4,287,200	-	Ribonuclease_P	K03536			
CDS	4,287,250	4,287,384	-	Ribosomal_L34	K02914	ICEAmeAS1IGenBankINC_0193931271627..1383296 Alteromonas mediterranea DE1, complete genome.	71	
CDS	4,287,896	4,289,569	-	DDE_Tnp_IS66				
CDS	4,289,595	4,289,759	-					

※ Row 7 to 764, 774 to 3460, 3505 to 4260 cannot be displayed due to lack of space. The complete version will be provided by Excel format.

Extended data Table 6. Gene annotations of *Tyzzarella nexilis* strain B1

Gene annotations of the *T.nexilis* strain B1 genome. Gene annotations based on Pfam, KEGG orthologies, and ICE-related genes are shown.

Extended data

Table 7

Demography	HC (n = 29)	RRMS (n = 62)	SPMS (n = 15)	p-value
Age, year	38.6 ± 2.28	39.0 ± 1.00	43.3 ± 2.60	0.26
Sex (female ; male)	17 ; 12	46 ; 16	9 ; 6	0.26
BMI, kg/m ²	21.4 ± 0.40	22.0 ± 0.41	21.3 ± 0.69	0.15
Onset age, year		30.0 ± 1.08	27.3 ± 2.25	0.27
Disease duration, year		9.0 ± 0.84	15.9 ± 1.54	0.0004
ARR		0.68 ± 0.11	0.13 ± 0.13	0.02
EDSS score		1.88 ± 0.17	5.53 ± 0.45	<0.0001
Immunotherapy				
Oral PSL, %		40 (n = 25)	60 (n = 9)	
IS, %		5 (n = 3)	27 (n = 4)	
DMDs				
IFN-β, %		37 (n = 23)	13 (n = 2)	
GA, %		5 (n = 3)	0	
FTY, %		6 (n = 4)	13 (n = 2)	
NTZ, %		0	7 (n = 1)	
DMF, %		3 (n = 2)	0	

Extended data Table 7. Demographics and characteristics of the patients and controls

Sixty-two patients with RRMS, 15 patients with SPMS, and 29 healthy controls were recruited. Data are represented as mean ± SEM. Abbreviations: BMI = body mass index; ARR = annual relapse rate; EDSS = expanded disability status scale; PSL = prednisolone; IS = immunosuppressive drugs; DMDs; disease-modifying drugs; IFN-β = interferon-β; GA = glatiramer acetate; FTY = fingolimod; NTZ = natalizumab; DMF = dimethyl fumarate; HC = healthy control; RRMS = relapsing-remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis.

Extended data

Table 8

ID	disease	site	ethnicity	age	sex	BMI	year of onset	disease duration	treatment status	treatments	EDSS score
RRMS_001	RRMS	Tokyo	Asian	41	F	24.2	15	26	Untreated	Untreated	1.5
RRMS_002	RRMS	Tokyo	Asian	32	M	23.1	16	16	Treated	Interferon	1
RRMS_003	RRMS	Tokyo	Asian	33	F	26.7	26	7	Treated	Interferon	1
RRMS_004	RRMS	Tokyo	Asian	43	F	23.6	34	9	Treated	Steroid	3.5
RRMS_005	RRMS	Tokyo	Asian	33	F	19.4	26	7	Untreated	Untreated	0
RRMS_006	RRMS	Tokyo	Asian	36	M	20.7	33	3	Untreated	Untreated	0
RRMS_007	RRMS	Tokyo	Asian	31	F	21.6	25	6	Untreated	Untreated	0
RRMS_008	RRMS	Tokyo	Asian	34	F	23.4	27	7	Treated	Interferon	1
RRMS_009	RRMS	Tokyo	Asian	44	F	19.1	38	6	Treated	Interferon	1
RRMS_010	RRMS	Tokyo	Asian	53	F	22.2	35	18	Treated	Steroid	3
RRMS_011	RRMS	Tokyo	Asian	40	F	19.7	21	19	Treated	Interferon	1
RRMS_012	RRMS	Tokyo	Asian	33	F	21.8	32	1	Untreated	Untreated	0
RRMS_013	RRMS	Tokyo	Asian	38	M	22.5	18	20	Treated	Interferon	2.5
RRMS_014	RRMS	Tokyo	Asian	41	F	23.1	35	6	Treated	Steroid	2
RRMS_015	RRMS	Tokyo	Asian	50	F	20.1	40	10	Treated	Steroid	7.5
RRMS_016	RRMS	Tokyo	Asian	30	F	32.4	26	4	Untreated	Untreated	2
RRMS_017	RRMS	Tokyo	Asian	35	M	20.5	22	13	Treated	Steroid	4
RRMS_018	RRMS	Tokyo	Asian	53	F	25.2	39	14	Treated	Steroid	4.5
RRMS_019	RRMS	Tokyo	Asian	26	F	18.7	23	3	Untreated	Untreated	2
RRMS_020	RRMS	Tokyo	Asian	43	F	20.7	39	4	Untreated	Untreated	1
RRMS_021	RRMS	Tokyo	Asian	33	F	20.1	19	14	Untreated	Untreated	1
RRMS_022	RRMS	Tokyo	Asian	44	F	19.6	22	22	Treated	Fingolimod + steroid	2
RRMS_023	RRMS	Tokyo	Asian	56	F	23.3	48	8	Treated	Steroid + immunosuppressant	1.5
RRMS_024	RRMS	Tokyo	Asian	30	M	25.6	18	12	Treated	Interferon	1.5
RRMS_025	RRMS	Tokyo	Asian	35	F	19.1	18	17	Treated	Interferon + steroid	3
RRMS_026	RRMS	Tokyo	Asian	35	M	26.7	25	10	Treated	Interferon	1
RRMS_027	RRMS	Tokyo	Asian	46	F	21.1	41	5	Treated	Interferon	1
RRMS_028	RRMS	Tokyo	Asian	36	F	21.8	23	13	Untreated	Untreated	1.5
RRMS_029	RRMS	Tokyo	Asian	37	F	22.8	25	12	Treated	Steroid	3
RRMS_030	RRMS	Tokyo	Asian	45	F	19.6	36	9	Treated	Steroid	1.5
RRMS_031	RRMS	Tokyo	Asian	46	M	23.7	40	6	Treated	Interferon + steroid	2
RRMS_032	RRMS	Tokyo	Asian	38	F	21.7	36	2	Untreated	Untreated	1
RRMS_033	RRMS	Tokyo	Asian	42	M	20.4	37	5	Treated	Interferon + steroid	3
RRMS_034	RRMS	Tokyo	Asian	37	F	17.2	31	6	Treated	Steroid	2
RRMS_035	RRMS	Tokyo	Asian	38	M	30.1	32	6	Treated	Dimethyl fumarate	1
RRMS_036	RRMS	Tokyo	Asian	35	F	17.3	23	12	Treated	Interferon	1
RRMS_037	RRMS	Tokyo	Asian	39	M	20.8	37	2	Treated	Interferon + steroid	0
RRMS_038	RRMS	Tokyo	Asian	25	F	24.2	22	3	Treated	Steroid	1
RRMS_039	RRMS	Tokyo	Asian	40	M	21.2	31	9	Treated	Steroid	2.5
RRMS_040	RRMS	Tokyo	Asian	38	F	26.0	30	8	Treated	Fingolimod	1
RRMS_041	RRMS	Tokyo	Asian	42	F	21.3	38	4	Treated	Steroid + immunosuppressant	2
RRMS_042	RRMS	Tokyo	Asian	31	F	19.8	30	1	Treated	Steroid	2
RRMS_043	RRMS	Tokyo	Asian	50	F	19.0	18	32	Treated	Fingolimod	3.5
RRMS_044	RRMS	Tokyo	Asian	33	F	23.4	30	3	Treated	Steroid	3
RRMS_045	RRMS	Tokyo	Asian	49	F	24.5	27	22	Treated	Steroid	4
RRMS_046	RRMS	Tokyo	Asian	49	F	30.4	44	5	Treated	Interferon	1.5
RRMS_047	RRMS	Tokyo	Asian	47	M	26.5	29	18	Treated	Interferon	1
RRMS_048	RRMS	Tokyo	Asian	44	F	23.4	29	15	Treated	Steroid	2.5
RRMS_049	RRMS	Tokyo	Asian	29	M	20.8	27	2	Treated	Glatiramer acetate	1
RRMS_050	RRMS	Tokyo	Asian	35	F	19.9	23	12	Treated	Interferon	1.5
RRMS_051	RRMS	Tokyo	Asian	34	F	20.7	34	0	Treated	Fingolimod	3.5
RRMS_052	RRMS	Tokyo	Asian	59	F	25.4	52	7	Treated	Glatiramer acetate	2
RRMS_053	RRMS	Tokyo	Asian	42	M	21.2	41	1	Treated	Interferon + steroid	3
RRMS_054	RRMS	Tokyo	Asian	23	M	16.7	22	1	Treated	Steroid	1
RRMS_055	RRMS	Tokyo	Asian	45	F	18.4	38	7	Treated	Interferon + steroid + immunosuppressant	3
RRMS_056	RRMS	Tokyo	Asian	37	M	23.4	27	10	Treated	Interferon	3.5
RRMS_057	RRMS	Tokyo	Asian	42	F	17.9	36	6	Treated	Interferon	1
RRMS_058	RRMS	Tokyo	Asian	32	F	19.2	24	8	Treated	Interferon	2.5
RRMS_059	RRMS	Tokyo	Asian	26	F	20.8	18	8	Treated	Interferon	1
RRMS_060	RRMS	Tokyo	Asian	36	F	16.4	33	3	Treated	Dimethyl fumarate	0
RRMS_061	RRMS	Tokyo	Asian	37	F	19.2	32	5	Untreated	Untreated	1
RRMS_062	RRMS	Tokyo	Asian	54	F	21.4	46	8	Treated	Glatiramer acetate	3
SPMS_001	SPMS	Tokyo	Asian	37	F	22.3	22	15	Treated	Steroid	6.5
SPMS_002	SPMS	Tokyo	Asian	39	F	19.7	27	12	Untreated	Untreated	3.5
SPMS_003	SPMS	Tokyo	Asian	42	M	19.9	32	10	Treated	Steroid	3.5
SPMS_004	SPMS	Tokyo	Asian	44	M	20.7	25	19	Treated	Interferon	7
SPMS_005	SPMS	Tokyo	Asian	33	M	19.9	24	9	Treated	Steroid	6
SPMS_006	SPMS	Tokyo	Asian	35	F	18.6	21	14	Treated	Steroid + immunosuppressant	4
SPMS_007	SPMS	Tokyo	Asian	39	F	21.3	18	21	Treated	Interferon + steroid	2.5
SPMS_008	SPMS	Tokyo	Asian	33	M	21.3	27	6	Treated	Fingolimod	6
SPMS_009	SPMS	Tokyo	Asian	42	M	29.1	32	10	Treated	Fingolimod	6
SPMS_010	SPMS	Tokyo	Asian	66	F	19.5	50	16	Treated	Steroid + immunosuppressant	7.5
SPMS_011	SPMS	Tokyo	Asian	46	F	18.4	20	26	Treated	Steroid + immunosuppressant	7
SPMS_012	SPMS	Tokyo	Asian	37	F	21.0	23	14	Treated	Steroid	6
SPMS_013	SPMS	Tokyo	Asian	53	M	21.2	31	22	Treated	Immunosuppressant	7
SPMS_014	SPMS	Tokyo	Asian	63	F	25.0	40	23	Treated	Natalizumab + steroid	7.5
SPMS_015	SPMS	Tokyo	Asian	40	F	21.2	18	22	Untreated	Untreated	3
HC_001	Control	Tokyo	Asian	32	M	26.2	N/A	N/A	N/A	N/A	N/A
HC_002	Control	Tokyo	Asian	46	F	20.7	N/A	N/A	N/A	N/A	N/A
HC_003	Control	Tokyo	Asian	31	M	25.9	N/A	N/A	N/A	N/A	N/A
HC_004	Control	Tokyo	Asian	47	M	17.6	N/A	N/A	N/A	N/A	N/A
HC_005	Control	Tokyo	Asian	57	F	21.5	N/A	N/A	N/A	N/A	N/A
HC_006	Control	Tokyo	Asian	65	F	19.1	N/A	N/A	N/A	N/A	N/A
HC_007	Control	Tokyo	Asian	61	F	21.7	N/A	N/A	N/A	N/A	N/A
HC_008	Control	Tokyo	Asian	30	F	21.2	N/A	N/A	N/A	N/A	N/A
HC_009	Control	Tokyo	Asian	60	F	22.2	N/A	N/A	N/A	N/A	N/A
HC_010	Control	Tokyo	Asian	25	F	21.9	N/A	N/A	N/A	N/A	N/A
HC_011	Control	Tokyo	Asian	62	M	24.1	N/A	N/A	N/A	N/A	N/A
HC_012	Control	Tokyo	Asian	28	F	18.1	N/A	N/A	N/A	N/A	N/A
HC_013	Control	Tokyo	Asian	23	F	19.7	N/A	N/A	N/A	N/A	N/A
HC_014	Control	Tokyo	Asian	31	M	23.9	N/A	N/A	N/A	N/A	N/A
HC_015	Control	Tokyo	Asian	33	M	22.5	N/A	N/A	N/A	N/A	N/A
HC_016	Control	Tokyo	Asian	35	M	21.2	N/A	N/A	N/A	N/A	N/A
HC_017	Control	Tokyo	Asian	29	F	20.9	N/A	N/A	N/A	N/A	N/A
HC_018	Control	Tokyo	Asian	30	M	22.7	N/A	N/A	N/A	N/A	N/A
HC_019	Control	Tokyo	Asian	26	M	21.8	N/A	N/A	N/A	N/A	N/A
HC_020	Control	Tokyo	Asian	24	F	21.5	N/A	N/A	N/A	N/A	N/A
HC_021	Control	Tokyo	Asian	47	F	18.8	N/A	N/A	N/A	N/A	N/A
HC_022	Control	Tokyo	Asian	43	F	23.5	N/A	N/A	N/A	N/A	N/A
HC_023	Control	Tokyo	Asian	36	M	20.9	N/A	N/A	N/A	N/A	N/A
HC_024	Control	Tokyo	Asian	37	F	19.4	N/A	N/A	N/A	N/A	N/A
HC_025	Control	Tokyo	Asian	35	M	21.9	N/A	N/A	N/A	N/A	N/A
HC_026	Control	Tokyo	Asian	31	F	23.2	N/A	N/A	N/A	N/A	N/A
HC_027	Control	Tokyo	Asian	35	F	18.0	N/A	N/A	N/A	N/A	N/A
HC_028	Control	Tokyo	Asian	42	M	22.4	N/A	N/A	N/A	N/A	N/A
HC_029	Control	Tokyo	Asian	37	F	19.2	N/A	N/A	N/A	N/A	N/A

Extended data Table 8. Clinical information of patients and controls

Detailed clinical information including recruitment site, ethnicity, age, sex, body mass index (BMI), year of onset, disease duration, treatments, and EDSS score is presented.